US20220091096A1 - Nanopores with internal protein adaptors - Google Patents
Nanopores with internal protein adaptors Download PDFInfo
- Publication number
- US20220091096A1 US20220091096A1 US17/487,164 US202117487164A US2022091096A1 US 20220091096 A1 US20220091096 A1 US 20220091096A1 US 202117487164 A US202117487164 A US 202117487164A US 2022091096 A1 US2022091096 A1 US 2022091096A1
- Authority
- US
- United States
- Prior art keywords
- nanopore
- protein
- adaptor
- ligand
- clya
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 194
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 183
- 239000003446 ligand Substances 0.000 claims abstract description 84
- 102000004190 Enzymes Human genes 0.000 claims abstract description 54
- 108090000790 Enzymes Proteins 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 33
- 230000008859 change Effects 0.000 claims abstract description 19
- 230000027455 binding Effects 0.000 claims description 91
- 108010022394 Threonine synthase Proteins 0.000 claims description 51
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 51
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims description 18
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims description 18
- 238000010494 dissociation reaction Methods 0.000 claims description 15
- 230000005593 dissociations Effects 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 10
- 102000004316 Oxidoreductases Human genes 0.000 claims description 9
- 108090000854 Oxidoreductases Proteins 0.000 claims description 9
- 108010056995 Perforin Proteins 0.000 claims description 9
- 102000004503 Perforin Human genes 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102220515257 Plasminogen activator inhibitor 2_N120D_mutation Human genes 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000012491 analyte Substances 0.000 abstract description 39
- 102000014914 Carrier Proteins Human genes 0.000 abstract description 5
- 108091008324 binding proteins Proteins 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 166
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 80
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 78
- 229960000485 methotrexate Drugs 0.000 description 75
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 62
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 49
- 229940088598 enzyme Drugs 0.000 description 42
- 239000011148 porous material Substances 0.000 description 36
- 239000011780 sodium chloride Substances 0.000 description 31
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 27
- 239000000758 substrate Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 239000000232 Lipid Bilayer Substances 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- 229960001230 asparagine Drugs 0.000 description 10
- 235000009582 asparagine Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229960003766 thrombin (human) Drugs 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 9
- 108091023037 Aptamer Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001351 cycling effect Effects 0.000 description 8
- 102000036202 glucose binding proteins Human genes 0.000 description 8
- 108091011004 glucose binding proteins Proteins 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 239000006142 Luria-Bertani Agar Substances 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 238000011533 pre-incubation Methods 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 6
- 241000208713 Dionaea Species 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- -1 for example Proteins 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 4
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000009010 Bradford assay Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010001267 Protein Subunits Proteins 0.000 description 3
- 102000002067 Protein Subunits Human genes 0.000 description 3
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 102000034238 globular proteins Human genes 0.000 description 3
- 108091005896 globular proteins Proteins 0.000 description 3
- 108010016102 glutamine transport proteins Proteins 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000000111 isothermal titration calorimetry Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- UKDDQGWMHWQMBI-UHFFFAOYSA-O 1,2-diphytanoyl-sn-glycero-3-phosphocholine Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C UKDDQGWMHWQMBI-UHFFFAOYSA-O 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- 239000004229 Alkannin Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108010013381 Porins Proteins 0.000 description 2
- 102000017033 Porins Human genes 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241001467018 Typhis Species 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000000055 blue native polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 102200097289 rs199472830 Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005460 tetrahydrofolate Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710183434 ATPase Proteins 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 101710200158 DNA packaging protein Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710158030 Endonuclease Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- BIMZLRFONYSTPT-UHFFFAOYSA-N N-oxalylglycine Chemical compound OC(=O)CNC(=O)C(O)=O BIMZLRFONYSTPT-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 108010084189 Pore Forming Cytotoxic Proteins Proteins 0.000 description 1
- 102000005576 Pore Forming Cytotoxic Proteins Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000003857 pore forming cytotoxic protein Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000004582 scanning ion conductance microscopy Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44791—Microapparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Definitions
- This application includes an electronically submitted sequence listing in .txt format.
- the .txt file contains a sequence listing entitled “O036670098US01-SEQ-KZM” created on Sep. 27, 2021 and is 24,656 bytes in size.
- the sequence listing contained in this .txt file is part of the specification and is hereby incorporated by reference herein in its entirety.
- the present invention relates to nanopore sensors comprising nanopore proteins and protein adaptors internalized in the lumen of the nanopores.
- the protein adaptor retains both its binding specificity for specific substrates and its functional activity, so that the nanopore sensor may be used for detecting analytes and characterizing unique properties of bound analytes.
- Nanopore analysis has emerged as a promising analytical tool for single-molecule analysis [Howorka, S. & Siwy, Z. (2009) Chem Soc Rev 38, 2360-2384; Bayley, H. (2015) Clin. chem. 61, 25-31; Luchian, T et al. (2003) Angew. Chem. 42, 3766-3771; Bezrukov, S. M. et al. (1994) Nature 370, 279-281]. Nanopore technology allows the investigation of native molecules with high sampling bandwidth without the need for labelling, chemical modifications or surface immobilisation. Further, the ionic current output signal can be easily interfaced with miniaturised and portable electronic devices.
- arrays of nanopores integrated into a MinIONTM sequencer have been recently used for the profiling of genomic DNA [Ashton, P. M. et al. (2014) Nat. Biotechnol. 33, 296-300; Mikheyev, A. S. & Tin, M. M. (2014) Mol. ecol. res. 14, 1097-1102; Quick, J. et al. (2014) GigaScience 3, 22.].
- biological nanopores have been reconstituted into bilayers formed on glass nanopipettes (White, R. J. et al (2007). J Am Chem Soc 129, 11766-11775) and on glass tips for scanning ion-conductance microscopy (Zhou, Y. et al (2014) Langmuir 30, 15351-15355). Therefore, nanopore-functionalized nanopipettes that can detect and quantify metabolites are promising platforms for measurement in single cells.
- Described herein is a nanopore sensor based on a nanopore and a protein adaptor that is internalized in the lumen of the nanopore.
- Different types of proteins, including enzymes, can be used.
- the protein adaptor remains in the lumen of the nanopore without the use of covalent chemistry or other immobilization techniques, and surprisingly, the protein adaptor retains its folded structure, function and/or binding properties.
- the binding of analytes to the internalized protein adaptor is reflected by changes in the nanopore conductance. Accordingly, methods for detecting analytes using the sensor are also described, and uses of the sensor in the discovery of new therapeutics and the detection of biomarker analytes in biological samples is disclosed.
- a first aspect of the present invention relates to a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, wherein the protein adaptor is a functional enzyme or ligand-binding protein.
- a first opening in the nanopore has a wider diameter than a second opening in the nanopore.
- the nanopore sensor is cytolysin A (ClyA) or a mutant or variant thereof.
- the protein adaptor is globular.
- the protein adaptor may be a functional enzyme selected from a demethylase and a reductase.
- the protein adaptor comprises a tag.
- the tag may have a net overall positive or negative charge.
- the protein adaptor forms a complex with one or more additional molecules. In some embodiments, the protein adaptor binds to a target analyte.
- the target analyte may be selected from a small molecule analyte, a protein analyte, and a nucleic acid analyte. In some embodiments, the target analyte is charged.
- the nanopore sensor is ClyA, and comprises a plurality of subunits, each subunit comprising an amino acid sequence represented by SEQ ID NO:3.
- the nanopore sensor is a demethylase, for example, AlkB demethylase.
- the nanopore sensor is a reductase, for example, dihydrofolate reductase.
- the demethylase is AlkB demethylase comprising an Asn120Asp mutation.
- Another aspect of the present invention relates to methods for detecting an analyte in a sample, comprising the steps of:
- the present invention thus discloses a method for detecting an analyte in a sample, comprising (a) obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, (b) adding the sample to the cis side or the trans side of the nanopore, and (c) measuring conductance across the nanopore, wherein a change in conductance after adding the sample indicates the analyte is present in the sample and has bound to the protein adaptor.
- the present invention thus discloses a method for identifying a ligand for a protein adaptor, comprising (a) obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, (b) adding a test compound to the cis side or the trans side of the nanopore, and (c) measuring the conductance across the nanopore, wherein a change in conductance after adding the test compound indicates that the test compound is a ligand that binds to the protein adaptor.
- the nanopore has a first and a second opening whereby the first opening has a wider diameter than the second opening.
- the nanopore is cytolysin A (ClyA) or a mutant or variant thereof such as cytolysin A (ClyA) mutant Gln56Trp.
- ClyA comprises a plurality of subunits, each subunit comprising an amino acid sequence represented by SEQ ID NO:3.
- the protein adaptor is globular.
- the protein adaptor is a demethylase enzyme or a reductase enzyme, such as AlkB demethylase (for example AlkB demethylase comprising an Asn120Asp mutation) or dihydrofolate reductase.
- a demethylase enzyme or a reductase enzyme such as AlkB demethylase (for example AlkB demethylase comprising an Asn120Asp mutation) or dihydrofolate reductase.
- the protein adaptor comprises a tag, which may have a net overall positive or negative charge.
- the protein adaptor forms a complex with one or more additional molecules.
- the analyte is a small molecule, a protein, or a nucleic acid. In specific embodiments the analyte is charged.
- Another aspect of the present invention is the use of a nanopore sensor as described above the detection of an analyte in a sample.
- the analyte is a small molecule, a protein, or a nucleic acid.
- the analyte is charged.
- FIGS. 1A-1C show internalization of AlkB-Fe ++ into ClyA-AS.
- FIG. 1A shows a cartoon representation of E. coli AlkB (green) containing a metal ion (Co 2+ , sphere) and binding to the cofactor (2-OG, labeled). The DNA binding site is depicted by an orange line. PDB_ID 3KHB.
- FIG. 1B shows the representation of a single AlkB-Fe ++ enzyme confined in a ClyA-AS nanopore (shown as cross-section) embedded in a planar lipid bilayer (labeled) under a negative applied potential. The dimensions of the pore consider the Van der Waals radii of the atoms.
- FIG. 1A shows a cartoon representation of E. coli AlkB (green) containing a metal ion (Co 2+ , sphere) and binding to the cofactor (2-OG, labeled). The DNA binding site is depicted by an orange line. PDB_
- FIG. 1C shows typical current blockades provoked by AlkB-Fe ++ molecules ( ⁇ 4 nM, cis) entering a ClyA-AS nanopore at ⁇ 60 mV.
- the open pore current (I O ) is represented by a blue dashed line, while Level 1 and Level 2 are shown by dashed lines, respectively.
- the asterisks represent the restoration of I O upon the exiting of AlkB-Fe ++ from the pore.
- the bottom panel shows the detail of a single AlkB-Fe ++ blockade, showing Level 1 and Level 2 current levels.
- the current traces were collected by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz.
- FIGS. 2A-2B show binding of ligands to AlkB-Fe ++ confined inside ClyA-AS.
- FIG. 2A shows a typical ligand-induced blockades to individual AlkB-Fe ++ enzymes confined inside ClyA-AS at ⁇ 60 mV. The ligand used is shown on the right of the trace.
- the bound Level 1 current levels (L 1O , L 1N , L 1S ) are represented by the lowermost dashed lines.
- the substrate concentration was 0.6 mM for 2-OG, 0.6 mM for N-OG and 2 mM for SUC binding to wild type AlkB-Fe ++ , and 7.2 mM for 2-OG binding to N120D-AlkB-Fe ++ .
- FIG. 2B shows dissociation rate constants (k off ) as a function of the ligand concentration at ⁇ 60 mV; while FIG. 2B (right panel) shows Event frequency (1/ ⁇ on ) as a function of the ligand concentration at ⁇ 60 mV.
- 2-OG is shown in squares, SUC in circles and N-OG in triangles.
- FIGS. 3A-3C show DHFR as a protein adaptor.
- FIG. 3A is a cartoon representation of E. coli DHFR (labeled) with bound methotrexate (MTX, spheres) and NADPH (spheres), PDB_ID 1RH3.
- FIG. 3B shows a representation of a single DHFR tag enzyme in complex with MTX confined in a ClyA-AS nanopore (shown as cross-section) embedded in a planar lipid bilayer (labeled) under a negative applied potential. The positively charged polypeptide tag added at the C-terminus of DHFR is labeled.
- FIG. 3A is a cartoon representation of E. coli DHFR (labeled) with bound methotrexate (MTX, spheres) and NADPH (spheres), PDB_ID 1RH3.
- FIG. 3B shows a representation of a single DHFR tag enzyme in complex with MTX confined in a ClyA-AS nano
- 3C shows typical current blockades provoked by the capture of DHFR tag :MTX complexes (20 nM DHFR tag , 400 nM MTX, cis) by the ClyA-AS nanopore at ⁇ 90 mV.
- the open pore current (I O ) is represented by the lowermost dashed line, while L 1M and L 2M are shown by the middle and uppermost dashed lines, respectively.
- Asterisks represent restoration of I O upon the exiting of DHFR tag :MTX from the pore.
- the current traces were collected in 150 mM NaCl, 15 mM Tris HCl pH 7.5, at 28° C. by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz.
- FIGS. 4A-4B show current enhancements upon ligand binding to DHFR tag
- FIG. 4A shows ligand-induced current enhancements to individual DHFR tag :MTX blockades at ⁇ 90 mV.
- NADP+ and NADPH were added to the trans compartment after addition of 20 nM DHFR tag and 400 nM MTX to the cis compartment. From top to bottom: no ligand; 5.7 ⁇ M of NADP+; 0.7 ⁇ M of NADPH; 7.4 ⁇ M of NADP+ together with 0.7 ⁇ M of NADPH.
- Free and bound Level 1 (L1 and L1o) are shown by dashed lines. Asterisks represent restoration of I O upon the exit of DHFR tag :MTX from the pore.
- FIG. 4B shows dissociation rate constants (k off ) as a function of the NADP+ concentration added to the trans compartment at ⁇ 90 mV.
- FIG. 4B shows event frequency (1/ ⁇ on ) as a function of the NADP+ concentration added to the trans compartment at ⁇ 90 mV. Errors are shown as standard deviations. All values for k off and f are based on >2000 binding events in total collected from N>8 single channel experiments with each experiment typically analysing n>20 DHFR tag :MTX blockades.
- FIG. 5 shows 2-OG induced binding events to a single AlkB-Fe ++ molecule.
- the current trace shows the capture of an AlkB-Fe ++ molecule (arrow) previously added to the cis compartment followed by the addition of 2-OG to the cis compartment.
- Confined AlkB-Fe ++ showed L1 and L2 current levels, while 2-OG binding induced L1B and L2B ionic current levels. (All current levels are labeled).
- the grey dashed line corresponds to the open pore current (I O ).
- the trace was recorded at ⁇ 60 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off.
- FIGS. 6A-6B show 2-OG induced current levels to AlkB-Fe ++ .
- FIG. 6A shows an extended current trace showing L1, L1B, L2 and L2B current levels induced by the binding of 2-OG to a single confined AlkB-Fe ++ .
- FIG. 6B are selected traces showing the details of the ligand-induced current levels. Transitions were always from L1B to L2B or from L1 to L2, or from L2 to L1 or from L2B to L1B. Current traces were recorded in presence of 4.8 mM 2-OG at ⁇ 60 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off.
- FIG. 7 shows NADP+ induced binding events to DHFR tag :MTX.
- the current trace shows DHFR tag :MTX (added to the cis compartment, 50 nM of DHFR tag and 400 nM MTX) blockades before (left) and after (right) the addition of 5.7 ⁇ M NADP+ (arrow) to the trans compartment.
- the binding of NADP+ results in reversible current enhancements from L1 M (uppermost dashed line) to L1 M:N+ (labeled).
- the grey dashed line (lowermost dashed line) corresponds to the open pore current (I O ).
- the trace was recorded at ⁇ 90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off.
- FIG. 8 shows the effect of the cognate Anti-AlkB aptamer on the AlkB-Fe ++ -induced current blockades.
- the addition of 40 ⁇ M cognate aptamer (TGCCTAGCGTTTCATTGTCCCTTCTTATTAGGTGATAATA, SEQ ID NO: 27, Table 5) reduced the frequency of the AlkB-Fe ++ blockades to ClyA-AS caused by 21 nM AlkB_Fe ++ due to electrostatic repulsion and/or steric hindrance between the AlkB:aptamer complexes and the negatively charged ClyA-AS lumen (Soskine, M. (2012) Nano Lett. 12, 4895-4900).
- the recordings were carried out in 150 mM NaCl, 15 mM Tris HCl pH 8.0 at 28° C. and ⁇ 35 mV applied potential.
- FIGS. 9A-9D show heterogeneity of NADPH and NADP+ binding to DHFR tag :MTX.
- the current traces show the capture of DHFR tag :MTX inside ClyA-AS (50 nM of DHFR tag and 400 nM of MTX added to the cis compartment), after the addition of 0.74 ⁇ M NADPH to the trans compartment.
- the uppermost dashed line represents the DHFR tag :MTX L1 M level.
- the asterisks indicate “short” (i.e. low affinity) NADPH binding events, while the solid lines indicate “long” (i.e. high affinity) NADPH induced binding events.
- FIG. 9A shows DHFR tag :MTX blockades displaying either “short” or “long” NADPH binding events.
- FIG. 9B shows the switching between “short” and “long” binding modes within the same DHFR tag :MTX blockade.
- FIGS. 9C and 9D show DHFR tag :MTX blockades (50 nM DHFR tag and 400 nM MTX in cis) after the addition of 5.7 ⁇ M NADP+ in trans.
- the dashed line represents the DHFR tag :MTX L1M level, the non-responsive state of the binary complex towards NADP+ is indicated by a solid line.
- the arrows indicate the capture of a new DHFR tag :MTX complex.
- the current trace in ( FIG. 9C ) shows DHFR tag :MTX blockades that are either responsive or non-responsive towards NADP+ addition.
- the current trace in ( FIG. 9D ) shows the switching between non-responsive and responsive states within the same DHFR tag :MTX blockade.
- the traces were recorded at ⁇ 90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off.
- FIG. 10 shows sequences of the 1+, 4+, tag (5 positive charges) and 10+ fusions to the DHFR C-terminus.
- the C-terminus of DHFR, the sequences of the S-tag, the positive coil and the Strep-tag are colored green, gray, cyan and yellow, respectively.
- the sequences of the flexible linkers are underlined.
- the positively charged amino acids in the polypeptide tags are indicated by an asterisk (*) and the negatively charged amino acids by a minus sign ( ⁇ ).
- FIG. 11 shows the purity of the strep-tagged purified wild type AlkB-Fe ++ assayed by a 12% SDS PAGE.
- a protein marker Page Ruler Plus Prestained Protein Ladder, Thermo scientific
- the right lane is 5 ⁇ g of the purified AlkB-Fe ++ .
- FIG. 12 shows the purity of the strep-tagged purified DHFR n+ assayed by a 15% SDS PAGE.
- lane 1 is a protein marker (Page Ruler Plus Prestained Protein Ladder, Thermo scientific).
- Lanes 2-4 contain ⁇ 5 ⁇ g each of purified DHFR (lane 2), DHFR 4+ (lane 3), DHFR tag (lane 4) and lane 5 contains ⁇ 10 ⁇ g of purified DHFR 10+ .
- FIGS. 13A-13D show DHFR n+ , DHFR n+ :MTX and DHFR n+ :MTX:NADPH induced current blockades to ClyA-AS nanopores.
- FIGS. 13B, 13C, 13D 0.7 ⁇ M of NADPH to the trans compartment
- FIGS. 13B, 13C, 13D right panel
- the arrows indicate NADPH binding events to the binary DHFR n+ :MTX complexes.
- the asterisks indicate the transition of DHFR 10+ :MTX to a lower conductance level.
- Current traces were recorded at ⁇ 90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Gaussian low-pass filter with 500 Hz cut-off.
- FIG. 14 SBD (substrate-binding domains) proteins with the ClyA nanopore.
- Right. Upper part, surface representation of SBD1 in the open configuration (PDB ID 4LA9).
- the proteins are colored according to their “in vacuum” electrostatics (red for negative regions and blue for positive regions, Pymol).
- FIGS. 15A-15D show the capture of SBD1 in Type I ClyA-AS
- FIG. 15A Typical ionic current blockades provoked by the capture of SBD1 (substrate-binding domain 1) (74 nM, cis) by the type I ClyA-AS nanopore at ⁇ 60 mV. The open pore, Level I and Level II current levels are indicated.
- FIG. 15B Detail of SBD1 current blockade before (upper part) and after addition of 0.40 ⁇ M asparagine (cis). The current traces were collected in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5 at 24° C.
- FIG. 15C K d values of SBD1 (74 nM, cis) for asparagine, obtained from the open (Level I) and closed ligand-bound (Level II) populations at the indicated substrate concentrations. Experiments were performed at ⁇ 60 mV.
- FIG. 15D Opening (k opening ) and closing (k closing ) rate constants of SBD1 determined from the transition rates of SBD1 molecules trapped in the nanopore at ⁇ 60 mV as a function of asparagine concentration. The k closing was obtained from the slope of the linear fit.
- FIGS. 16A-16C show capture of SBD2.
- FIG. 16A Typical current blockade provoked by the capture of SBD2 (70 nM, cis) by the type I ClyA-AS nanopore at ⁇ 100 mV before (left) and after addition of 0.40 ⁇ M glutamine cis.
- the current traces were collected in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5 at 24° C. by applying a Bessel low-pass filter with a 2 kHz cut off and sampled at 10 kHz. A post-aqcuisition Gaussian filter of 100 Hz was applied.
- FIG. 16A Typical current blockade provoked by the capture of SBD2 (70 nM, cis) by the type I ClyA-AS nanopore at ⁇ 100 mV before (left) and after addition of 0.40 ⁇ M glutamine cis.
- the current traces were collected in 150 mM NaCl, 15 mM Tris
- FIG. 16B K d values of SBD2 (70 nM, cis) for glutamine, obtained from Level II (bound state), and level I and Level III at the indicated substrate concentrations. Experiments were performed at ⁇ 100 mV.
- FIG. 16C Opening (k opening ) and closing (k closing ) rate constants of SBD2.
- FIG. 17 shows that inactive SBD2 does not bind to glutamine.
- Typical current blockade provoked by the capture of E417W-SBD2 (cis) by the type I ClyA-AS nanopore at ⁇ 100 mV before (left) and after addition of 200 ⁇ M glutamine cis.
- Red asterisks represent the restoration of I O upon the exiting of SBD2_D417F from the pore.
- Level I and Level II transition most likely represent the entry of SBD2 into ClyA nanopores in two different configurations.
- FIGS. 18A-18C Glucose sensing with a venus flytrap protein domain.
- FIG. 18 a Cut-through a ClyA nanopore containing a GBP.
- FIG. 18 b Cartoon representation of the open (blue) and closed (orange) configuration of the venus flytrap domain of GBP.
- FIG. 18 c Electrical recording of the GPB blocked current in the absence (top) and presence (middle and bottom) of increasing concentrations of glucose.
- FIGS. 19A-19C show protein recognition with ClyA variants.
- FIG. 19A Cut through a ClyA-AS nanopore showing the incorporation of HT. The protein lodges in two sites inside the nanopore which are called L1 and L2.
- FIG. 19B Ionic current blockades of HT inside ClyA-AS showing the movement of HT between L1 and L2 at ⁇ 35 mV.
- FIG. 19C Percentage of L1 and L2 residence inside ClyA-AS for different ClyA-AS mutants.
- FIG. 20 Shows the effect of nanopore mutations on Human thrombin blockades.
- the figure indicate the blockades induced by human thrombin at ⁇ 35, ⁇ 50 and ⁇ 80 mV (from top to bottom) to ClyA-AS-WT, CLyA-AS-125W and ClyA-AS-v60w (from left to right).
- the blockades induced by human thrombin are similar for ClyA-AS-WT and CLyA-AS-125W, and differ for ClyA-AS-v60w, indicating that thrombin binding site is close to the position 60 inside the ClyA nanopore.
- FIGS. 21A-21B show analyte recognition with ClyA nanopores.
- FIG. 21A Binding of Glutamine to SBD2 inside a ClyA-AS nanopore.
- Level I and Level III correspond to the open SBD2 configuration (see word file), while Level II corresponds to the ligand bound configuration.
- FIG. 21B mutant screened showing the difference between level I, Level II and Level III (as residual current %).
- Q56W provides the better recognition.
- FIG. 22 shows SBD2 blockades to ClyA-AS-q56w.
- the signal due to the binding of glutamine to the internalized adaptor (level L2) is enhanced when compared to the signal measured for the ClyA-WT pore ( FIGS. 21A-21B )
- Proteins have evolved to identify their ligands with high specificity in a sea of very similar chemical species. Accordingly, a nanopore which has incorporated protein adaptors in the lumen of the nanopore is well-suited for use in detecting ligand analytes.
- the conformational change in the protein adaptor and/or presence of the target analyte bound to the protein adaptor is measured as a change in nanopore conductance, for example, as an increase in the ionic current blockade events in the nanopore.
- nanopore sensors comprising a nanopore (also called “pore,” “pore protein,” or “nanopore protein”) and a protein adaptor (or “adaptor” or “internalized protein” or “protein”) which is fully or partially internalized (or “contained,” “incorporated,” “trapped,” “set,” “accommodated,” “residing,” “embedded,” or “confined”) within the lumen of the nanopore.
- a nanopore also called “pore,” “pore protein,” or “nanopore protein”
- protein adaptor or “internalized protein” or “protein”
- Exemplary nanopores include, but are not limited to cytolysins, hemolysins, porins, DNA packaging protein, and motor proteins.
- the nanopore is Phi29 (Wendell, D. et al. (2009) Nat. nanotech. 4, 765-772), pneumolysin (Gilbert, R. J. et al. (1999) Cell 97, 647-655), FhuA (Niedzwiecki D J et al. (2012) Biophys J. 103, 2115-2124) or a solid-state nanopores.
- the nanopore is a pore-forming cytotoxic protein, for example, a bacterial cytolysin.
- the nanopore is a cytolysin from a gram-negative bacteria such as Salmonella or Escherichia coli ( E. coli ).
- the nanopore is Cytolysin A (ClyA) from Salmonella typhi ( S. typhi ) or Salmonella paratyphi (S. paratyphi).
- the nanopore is a mutant or variant of ClyA, such as a modified variant of ClyA like ClyA-CS or ClyA-AS as described in WO2014153625.
- the nanopore is cylindrically shaped with at least 2 openings, for example, a cis opening and a trans opening.
- a first opening may have a larger diameter than a second opening in the nanopore.
- the cis opening has a larger diameter than the trans opening.
- the “cis diameter” is wider than the “trans diameter.”
- the trans opening may have a larger diameter than the cis opening.
- a nanopore is an oligomeric structure comprising subunits (or “monomers”), and the size of the pore lumen depends on the number and/or composition of subunits in the oligomeric structure.
- the nanopore may comprise at least 7 monomers, for example, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 monomer subunits. In some embodiments, the nanopore comprises at least 20 monomer subunits, for example, 20-25, 25-30, 35-40, or 45-50 subunits. In certain embodiments, the nanopore comprises 12 subunits. In further embodiments, the nanopore comprises 13 subunits, or 14 subunits. The subunits may preferentially assemble in 12 mers and/or 13 mers, depending on the amino acid sequence of the subunits.
- the nanopores comprise subunits which may be assembled into different oligomeric forms.
- each of the subunits may be identical, or the subunits may be different, so that subunits in a pore may comprise sequences that differ from sequences of other polypeptide subunits in the same nanopore.
- nanopores as disclosed herein, such as ClyA nanopores or variants such as ClyA-CS and ClyA-AS may form more than one subtype depending on subunit composition. For example, there may be at least 2 or 3 different subtypes of subunits in the nanopore, depending on the composition of the subunits.
- ClyA-AS [Mueller, M. et al.
- Soskine, M. et al. (2013) J Am Chem Soc, 135, 13456-13463] may be assembled into at least 3 oligomeric forms (Type I, Type II and Type III ClyA) (Soskine, M. et al. (2013) J Am Chem Soc, 135, 13456-13463) that are large enough to accommodate proteins or protein-DNA complexes (Van Meervelt, V. et al (2014) ACS nano, 8, 128262-12835).
- Any nanopore that is assembled from individual subunits may have different oligomeric forms, and the oligomeric forms may vary in properties such as size and voltage dependent opening and closing (gating) of the nanopore.
- Subtypes may be preferentially formed by subunits of a particular polypeptide sequence.
- the nanopore is ClyA from Salmonella typhi and comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence at least 80% identical to SEQ ID NO: 1.
- the subunits are represented by an amino acid sequence at least 85% identical, 90% identical, 95% identical, 99% identical or 100% identical to SEQ ID NO:1.
- Identical may refer to amino acid identity, or may refer to structural and/or functional identity. Accordingly, one or more amino acids may be substituted, deleted, and/or added, as compared with SEQ ID NO:1.
- Modifications may alter the pore lumen in order to alter the size, binding properties, and/or structure of the pore. Modifications may also alter the ClyA nanopore outside of the lumen.
- the ClyA nanopore comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), and wherein exactly one Cys residue is substituted with Ser.
- the Cys residue may be Cys 87 and/or Cys 285 in SEQ ID NO:1.
- the Cys residue is Cys285.
- the remaining amino acid residues may also be substituted, for example, with amino acids that share similar properties such as structure, charge, hydrophobicity, or hydrophilicity.
- substituted residues are one or more of L99, E103, F166, and K294.
- the substituted residues may be one or more of L99Q, E103G, F166Y, and K294R.
- An exemplary subunit may comprise substitutions L99Q, E103G, F166Y, K294R, and C285S.
- each subunit may comprise a polypeptide represented by an amino acid sequence of SEQ ID NO:2.
- An exemplary ClyA nanopore comprising subunits in which exactly one Cys residue is substituted with Ser may be called ClyA-CS.
- ClyA mutants of the present invention are variants with a mutation at Ser110, Lys125, Val67, Val60, Gln56 or Arg49. Specific embodiments of such variants are Lys125Trp, Val60Trp and Gln56Trp.
- the ClyA nanopore comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), and wherein exactly one Cys residue is substituted with Ala.
- the cysteine residue may be Cys 87 or Cys 285 in SEQ ID NO:1.
- each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), wherein one Cys residue is substituted with Ser and/or exactly one Cys residue is substituted with Ala.
- the cysteine residues may be Cys87 or Cys285 in SEQ ID NO:1.
- Other amino acid residues may be substituted, for example, with amino acids that share similar properties such as structure, charge, hydrophobicity, or hydrophilicity.
- substituted residues are one or more of L99, E103, F166, K294, L203 and H207.
- the substituted residues may be L99Q, E103G, F166Y, K294R, L203V, and H207Y.
- An exemplary subunit may comprise L99Q, E103G, F166Y, K294R, L203V, and H207Y, and C285S.
- each subunit may comprise a polypeptide represented by an amino acid sequence of SEQ ID NO:3.
- An exemplary ClyA nanopore comprising subunits in which exactly one Cys residue is substituted with Ser and exactly one Cys residue is substituted with Ala may be called ClyA-AS.
- a nucleic acid encoding a modified ClyA nanopore is represented by a nucleotide sequence that is at least 80%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:4.
- a nucleic acid may be represented by SEQ ID NO: 5 or SEQ ID NO:6.
- Nucleotide sequences may be codon optimized for expression in suitable hosts, for example, E. coli.
- the lumen of the nanopore is large enough to accommodate a protein adaptor that is folded and is either (1) not bound or (2) bound to a target such as a specific target analyte.
- the protein adaptor may be complexed with one or more additional molecules such as a co-factor or substrate or inhibitor to form a protein adaptor complex (or “adaptor complex”).
- the protein adaptor may bind non-specifically and/or with low affinity to non-targets before binding with high affinity to its target, particularly if the non-targets are chemically similar to the target.
- the protein adaptor may be exposed to a variety of analytes that are not its target analyte.
- the protein adaptor may also undergo conformational changes within the lumen of the nanopore upon binding to its target analyte.
- the lumen of the nanopore is at least 3 nm in diameter, for example, the diameter may measure 3 nm, 3.5 nm, 4 nm, 4.5 nm, 5 nm, 5.5 nm, 6 nm, 6.5 nm, 7 nm, or greater.
- the cis diameter of the nanopore lumen may be at least 3.5 nm and/or the trans diameter of the nanopore may be at least 6 nm.
- cis refers to the end of the modified pore to which an analyte is added, while trans refers to the end of the modified nanopore through which the analyte exits after translocating the length of the nanopore lumen.
- the trans end of a pore may be inserted in the lipid bilayer, while the cis end of the nanopore remains on the same side of the lipid bilayer.
- the cis diameter of the nanopore is the diameter of the opening at the cis end of the nanopore
- the trans diameter of the nanopore is the diameter at the opening of the opposite trans end of the nanopore.
- An analyte may be added to either side of the nanopore, for example, an analyte may be added to the cis opening of the nanopore so that it transverses the nanopore and exits from the trans side. Alternatively, an analyte may be added to the trans side of the nanopore.
- Nanopores are typically arrayed in a membrane such as a lipid bilayer, across which a potential can be applied.
- the applied potential across the membrane refers to the potential of the trans electrode.
- Nanopores may be inserted into lipid bilayers from the cis compartment, which are connected to a ground electrode.
- protein adaptors may be fully or partially incorporated in the lumen of nanopores to form the nanopore sensors.
- the protein adaptors are globular proteins (also called “spheroproteins”).
- the protein adaptors may be roughly spherical and may form colloids in water.
- the protein adaptors may be characterized by apolar (hydrophobic) amino acids that are bounded towards the molecule's interior while polar (hydrophilic) amino acids are bound outwards.
- the protein adaptor is a single protein. In certain embodiments, the protein adaptor is a protein domains, oligomers, and/or fragment of a protein. The protein adaptor may also be a complex or combination of single proteins and/or fragments. In certain embodiments, the protein adaptor complex comprises a protein (or fragments or domains) complexed with a small analyte such as a small molecule and/or an inhibitor. In certain embodiments, the protein adaptor is a functional enzyme. In certain embodiments, the protein adaptor is a ligand-binding domain.
- the protein adaptor must have dimensions that fit into a nanopore, for example, the protein adaptor may have a diameter that is smaller than the cis-diameter of the nanopore but larger than the trans-diameter of the nanopore. In some exemplary nanopores, the cis-diameter is wider than the trans-diameter, so the protein adaptor may pass through the cis end of the nanopore but not through the trans end.
- the protein adaptor may remain internalized for at least 0.1-1 ⁇ s, 1-10 ⁇ s, or 10-100 ⁇ s.
- the cis-diameter of the nanopore may be at least 4.5 nm, 5.0 nm, 5.5 nm, 6.0 nm, 6.5 nm, or 7 nm, while the trans-diameter of the nanopore is at least 1.5 nm, 2.0 nm, 3.0 nm, 3.3 nm, 3.5 nm, or 4.0 nm.
- the cis-diameter of the nanopore is 5.5 nm and the trans-diameter of the nanopore is about 3.0 nm, for example 3.3 nm.
- a protein adaptor suitable for internalization in the nanopore may have an average diameter that is smaller than the cis-diameter of the nanopore (for example, smaller than 5.5 nm) but larger than the trans-diameter of the nanopore (for example, larger than 3.0 nm or 3.3 nm). Accordingly, such a protein adaptor added to the cis side of the nanopore would be able to enter the nanopore but would not exit from the trans side of the nanopore. Conversely, if the trans-diameter were larger than the cis-diameter, then a protein adaptor added to the trans side of the nanopore would enter through the trans-opening but would not exit from the cis-opening.
- the average diameter of the protein adaptor may be determined by examination of the crystal structure, if available, or by estimation based on measurements such as molecular weight. For example, a protein with a molecular weight of about 20 kDa may be expected to have an average diameter of less than 3.5 nm, while a protein with a molecular weight of about 25 kDa may be expected to have an average diameter of more than 3.5 nm.
- Nanopores typically have lumens that are either negatively or positively charged, as the charge is required for the electroosmotic flow of charged molecules (e.g., analytes) through the nanopore when an electric field is applied across the nanopore.
- charged molecules e.g., analytes
- a nanopore has a negatively-charged lumen and a negative potential is applied to one side of the nanopore (e.g., the trans side of the nanopore)
- a positively charged molecule will pass freely through the nanopore from the cis end to the trans end.
- protein adaptors suitable for internalization in the nanopore may be positively- or negatively-charged. Charges are not limiting for the incorporation of the protein adaptor.
- moderately negatively-charged molecules pI>4-isoelectric point
- Some protein adaptors are either too small to remain internalized in the nanopore and/or have a charge is not suitable for entry into the nanopore (i.e., a nanopore has a negatively-charged lumen but the protein has a highly negative charge).
- a protein has an average diameter that is smaller than both diameters of the nanopore, the protein may not be expected to remain internalized in the nanopore lumen.
- a protein that has an average diameter of less than 3.5 nm would not be expected to remain internalized for longer than a few milliseconds in a nanopore whose cis diameter is about 6.5 nm and whose trans diameter is about 3.5 nm.
- a protein adaptor is tagged in order to be internalized in the nanopore and/or to be retained in the lumen of the nanopore.
- the tag may be a charged tag.
- a protein may have a positively-charged tag in order to be internalized in a negatively-charged nanopore.
- the tag may be attached covalently or by other chemical means, or the tag may be present as a fusion with the protein adaptor, for example, the protein adaptor and tag may have been genetically encoded.
- a tag comprises at least 4, 5, 6, 7, 8, 9, or 10 positively charged amino acid residues.
- Tags may comprise positively charged coils, spacers (e.g., flexible linkers), and/or labels for purification (e.g., strep tags).
- spacers e.g., flexible linkers
- labels for purification e.g., strep tags.
- the presence of a tag increases the retention time of the tagged protein adaptor by 100-fold or 1000-fold. Accordingly, the tagged protein adaptor may remain internalized in the nanopore for seconds whereas the untagged protein adaptor alone would only be internalized for milliseconds.
- the protein adaptor is an enzyme (also called an “enzyme adaptor”).
- the enzyme may be an oxidoreducase (Enzyme Commission (EC) 1), transferase (EC2), hydrolase (EC3), lyase (EC4), isomerase (EC5), or ligase (EC6).
- the enzyme may be selected from a demethylase or a reductase.
- the enzyme is a demethylase.
- the enzyme may be AlkB demethylase.
- the enzyme is a reductase, such as dihydrofolate reductase (DHFR).
- the protein adaptor may be complexed with a molecule such as a small molecule (e.g., co-factor, inhibitor, and/or any other small molecule that binds to the protein adaptor) to form an adaptor complex, and this adaptor complex may bind to a target analyte.
- a small molecule e.g., co-factor, inhibitor, and/or any other small molecule that binds to the protein adaptor
- DHFR may be complexed with methotrexate (MTX) to form an adaptor complex.
- MTX methotrexate
- the protein adaptor comprises protein subunits, fragments, and/or domains of proteins.
- a protein subunit, fragment, or domain may be suitable for internalization, or may be made suitable by adding tags to increase size and/or charge.
- a protein adaptor complex may comprise a protein subunit, fragment, or domain.
- exemplary protein adaptors include but are not limited to antibodies, nanobodies, artificially designed binding elements, ligand binding proteins (for example, venus fly trap domains), transcription factors, metal-binding proteins, intrinsically unfolded binders, and more.
- Analytes include small molecules, including organic and inorganic molecules, and biological molecules such as proteins and nucleic acids. Analytes may be charged or may be uncharged molecules. In some embodiments, the analytes detected by the nanopore sensors disclosed herein are charged molecules. The charged molecules may be proteins or small molecules.
- Analytes may be known targets of the protein adaptor, for example, if the nanopore is used to determine whether a known binding partner of the protein adaptor is present in a mixture.
- new binding partners for the protein adaptor may be identified, for example, by screening a library of compounds or molecules which were not previously known to bind to the protein adaptor.
- one aspect of the present invention relates to a method for detecting an analyte in a sample, comprising obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, adding the sample to the cis side or the trans side of the nanopore, and measuring conductance across the nanopore, wherein a change in conductance after adding the sample indicates that the analyte is present in the sample and has bound to the protein adaptor.
- conductance is measured continuously before, during, and after addition of the analyte.
- a further aspect relates to a method for identifying a ligand for a protein adaptor, comprising obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, adding a test compound to the cis side or the trans side of the nanopore, and measuring the conductance across the nanopore, wherein a change in conductance after adding the test compound indicates that the test compound is a ligand that binds to the protein adaptor.
- the change in conductance is a change in the current blockades (I B ), i.e., residual currents calculated as a percentage of the open pore current (I RES % ).
- I B current blockades
- I RES % open pore current
- binding of an analyte to the protein adaptor may cause an increase in current blockades.
- the current blockade is decreased.
- the change in current conductance is a measurable change in the noise pattern.
- Conductance across the nanopore is sensitive and highly specific to the identity of the ligand that binds to the protein adaptor. Conductance measurements may be used to differentiate between two ligands that differ from one another by a single atom. For example, the binding of a protein adaptor (or adaptor complex) to a specific substrate has a different conductance than the binding of the protein adaptor (or adaptor complex) to the substrate that lacks a hydride ion. Thus, binding of an internalized protein to NADPH may be distinguished from binding of the internalized protein to NADP+.
- a protein adaptors may be an enzyme (“enzyme adaptor,” “internalized enzyme,” or “enzyme”), and various aspects of enzyme binding, activity, and function may be studied using a nanopore sensor comprising a nanopore and an enzyme adaptor.
- a further aspect of the present disclosure relates to a method for measuring enzyme kinetics, comprising obtaining a nanopore sensor comprising a nanopore and an enzyme adaptor internalized in the lumen of the nanopore, adding a ligand to the cis side or the trans side of the nanopore, measuring a first conductance change across the nanopore which reflects binding of the ligand to the enzyme adaptor, and measuring additional conductance changes across the nanopore which reflect enzyme kinetics such as association and dissociation of the ligand and the enzyme adaptor.
- the measurements are obtained continuously over time while the ligand concentration is varied (e.g., increased).
- the method further comprises increasing the applied potential across the nanopore until the ligand dissociates from the enzyme adaptor, and the dissociation is measured by a change in conductance (for example, a decrease or increase in I B ). In certain embodiments, the method further comprises decreasing the applied potential across the nanopore until the ligand binds to the enzyme adaptor, and the binding is measured by a change in conductance (for example, an increase or decrease in I B ).
- an additional aspect of the present disclosure relates to a method for measuring activity of an enzyme adaptor on a substrate, comprising obtaining a nanopore sensor comprising a nanopore and an enzyme adaptor internalized in the lumen of the nanopore, adding the substrate to the cis side or the trans side of the nanopore, and measuring conductance across the nanopore, wherein a change in conductance after adding the ligand indicates activity of the enzyme adaptor on the substrate.
- the activity may be binding, cleavage, conformational changes, and/or other changes mediated by enzymes acting on their substrate.
- competitive binding between two substrates can be monitored by conductance changes as the substrates bind and dissociate with the enzyme adaptor.
- a Nco I site (CCATGG) was introduced in the wild type AlkB from E. coli at the beginning of the gene (5′ end). To keep the gene in reading frame an additional two bases were inserted after the Nco I site, resulting in an additional alanine residue after the starting methionine.
- CCATGG Nco I site
- a strep-tag was attached via a flexible glycine-serine-alanine linker and the open reading frame was terminated by two consecutive stop codons, followed by a Hind III restriction site (3′ end). The attachment of the strep-tag was carried out in two consecutive PCR reactions.
- the AlkB gene was amplified directly from the genomic DNA of a single BL21(DE3) E. coli (Lucigen) colony using Phire Hot Start II DNA polymerase (Finnzymes), 6 ⁇ M fAlkB (Table 5) and AlkBr1 (Table 5) primers in a 50 ⁇ L reaction volume.
- the PCR reaction cycling protocol was as follows: pre-incubation step at 98° C. for 30 s and then 30 cycles of denaturation at 98° C. for 5 s and extension at 72° C. for 1 min.
- the amplified product was purified using QIAquick PCR Purification Kit (Qiagen) and served as a template for the second PCR reaction, which used ⁇ 100 ng of the purified PCR product amplified by Phire Hot Start II DNA polymerase using 6 ⁇ M of fAlkB (Table 5) and AlkBr2 (Table 5) primers in 300 ⁇ L volume.
- the cycling protocol was the same as in the previous step.
- the resulting PCR product containing the strep-tagged AlkB gene was purified with QIAquick PCR Purification Kit (Qiagen) and digested with Nco I and Hind III (FastDigest, Fermentas).
- the gel purified insert (QIAquick Gel Extraction Kit, Qiagen) was cloned under control of the T7 promoter into the pT7-SC1 expression plasmid using sticky-end ligation (T4 ligase, Fermentas) via Nco I (5′) and Hind III (3′) sites.
- T4 ligase sticky-end ligation
- Nco I 5′
- Hind III 3′
- the synthetic gene encoding for E. coli DHFR was made by GenScript.
- the wild-type gene was modified by the substitution of the two Cys residues at positions 85 and 152 with Ala and Ser respectively (referred to as DHFR throughout SI and main text). Those substitutions were shown to be functionally tolerated by DHFR (Plesa, C. et al. (2013) Nano Lett., 13, 658-663).
- the DNA sequence encoding for Met-Ala-Ser-Ala was added at the beginning of the gene in order to introduce a Nco I restriction site. To facilitate construction steps, a Xho I restriction site was introduced between the C-terminal tags and DHFR.
- the DHFR 10+ construct was built ( FIG. 10 , for DNA and protein sequence see below).
- 100 ng of the synthetic DHFR gene was amplified with 5 ⁇ M of DHf and DHr primers (Table 5) with Phire Hot Start II DNA polymerase (Finnzymes) in 400 ⁇ L final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1 min for 30 cycles).
- the synthetic fragment encoding for the 10+ tag (made by IDT, for sequence see below) was amplified as described above using Cof and Cor primers (Table 5).
- DHf and Cof primers contain sequences that are the reverse-complement of each other, introducing sequence overlap between DHFR and 10+ tag PCR products, necessary for the next step, where both PCR products (2 ⁇ g each, gel-purified, QIAquick Gel Extraction Kit, Qiagen) were assembled together using Phire Hot Start II DNA polymerase (Finnzymes) in 50 ⁇ L final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1 min for 7 cycles).
- PCR product encoding for the whole length DHFR 10+ was purified using the QIAquick PCR Purification Kit (Qiagen) and digested with Nco I and Hind III (FastDigest, Fermentas).
- the resulting insert was gel purified and cloned under control of the T7 promoter into the pT7-SC1 expression plasmid [Miles, G. et al. (2001) Biochem. 40, 8514-8522] using sticky-end ligation (T4 ligase, Fermentas) via Nco I (5′) and Hind III (3′) sites.
- T4 ligase, Fermentas sticky-end ligation
- Nco I 5′
- Hind III (3′) sites 0.6 ⁇ L of the ligation mixture was transformed into E. Cloni® 10G cells (Lucigen) by electroporation.
- the transformed bacteria were selected overnight at 37° C. on ampicillin (100 ⁇ g/ml) LB agar plates.
- the identity of the clones was confirmed by sequencing.
- the DNA and protein sequence of DHFR 10+ is provided below with the 10+ tag sequence indicated by capital letters in the DNA sequence.
- DHFR, DHFR 4+ and DHFR tag constructs were built by deleting parts of the 10+ tag via whole plasmid PCR amplification followed by Xho I digestion and unimolecular ligation as follows: ⁇ 100 ng of the DHFR_10+ tag plasmid was amplified using 5 ⁇ M of dcr and delF (to produce DHFR), or 2dcF (DHFR 4+ ) or dcf (DHFR tag ) using Phire Hot Start II DNA polymerase (Finnzymes) in 100 ⁇ L final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C.
- PCR products were purified with QIAquick PCR Purification Kit (Qiagen), digested with Xho I (FastDigest, Fermentas) and ligated with T4 ligase (Fermentas). 0.6 ⁇ L of the ligation mixture was transformed into E. Cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were selected overnight at 37° C. on ampicillin (100 ⁇ g/ml) LB agar plates. The identity of the clones was confirmed by sequencing.
- the AlkB gene was amplified using 120D (forward) and T7 terminator (reverse) primers (Table 5).
- the PCR conditions were: 0.3 mL final volume of PCR mix (150 ⁇ l of RED Taq ReadyMix, 6 ⁇ M of forward and reverse primers, ⁇ 400 ng of template plasmid), cycled for 27 times (after a pre-incubation step at 95° C. for 3 min, a cycling protocol was then applied: denaturation at 95° C. for 15 s, annealing at 55° C. for 15 s, extension at 72° C. for 3 min).
- the resulting PCR product was gel purified (QIAquick Gel Extraction Kit, Qiagen) and cloned into a pT7 expression plasmid (pT7-SC1) by MEGAWHOP procedure [Miyazaki, K. (2011) Methods Enzymol 498, 399-406]: ⁇ 500 ng of the purified PCR product was mixed with ⁇ 300 ng of the WT AlkB circular DNA template and the amplification was carried out with Phire Hot Start II DNA polymerase (Finnzymes) in 50 ⁇ L final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1.5 min for 30 cycles).
- Phire Hot Start II DNA polymerase Phire Hot Start II DNA polymerase
- the circular template was eliminated by incubation with Dpn I (1 FDU) for 2 hr at 37° C.
- 0.6 ⁇ L of the resulted mixture was transformed into 50 ⁇ L of E. Cloni® 10G cells (Lucigen) by electroporation.
- the transformed bacteria were grown overnight at 37° C. on ampicillin (100 ⁇ g/ml) LB agar plates. The identity of the clones was confirmed by sequencing.
- pT7-SC1 plasmids containing the strep-tagged AlkB gene were transformed into E. Cloni® EXPRESS BL21(DE3) cells (Lucigen). Transformants were selected on LB agar plates supplemented with 100 ⁇ g/ml ampicillin grown overnight at 37° C. The resulting colonies were grown at 37° C. (200 rpm shaking) in 2xYT medium supplemented with 100 ⁇ g/ml ampicillin until the O.D. at 600 nm was ⁇ 0.8.
- the cultures were then supplemented with 25 ⁇ M FeSO 4 and 100 ⁇ M L(+)-ascorbic acid (Merck) from fresh stock solutions (25 mM FeSO 4 and 100 mM L(+)-ascorbic acid in ddH 2 O) and the protein expression was induced by supplementing with 0.5 mM IPTG.
- Bacteria were further grown overnight at 25° C., 200 rpm shaking. The next day the bacteria were harvested by centrifugation at 6000 ⁇ g at 4° C. for 25 min. The resulting pellets were frozen at ⁇ 80° C. until further use.
- AlkB-Fe ++ was purified as following: bacterial pellets originating from 100 ml culture were resuspended in 30 ml lysis buffer (150 mM NaCl, 15 mM Tris.HCl pH 8.0, 1 mM MgCl 2 , 0.2 units/ml DNase, 10 ⁇ g/ml lysozyme) supplemented with 5 ⁇ l ⁇ -mercaptoethanol (Merck) and 25 ⁇ M FeSO 4 and 100 ⁇ M L(+)-ascorbic acid, and incubated at RT for 20 min. Bacteria were further disrupted by probe sonication, and the crude lysate was clarified by centrifugation at 6000 ⁇ g at 4° C.
- lysis buffer 150 mM NaCl, 15 mM Tris.HCl pH 8.0, 1 mM MgCl 2 , 0.2 units/ml DNase, 10 ⁇ g/ml lysozyme
- the resin was loaded on a column (Micro Bio Spin, Bio-Rad) and washed with ⁇ 20 column volumes of the wash buffer supplemented with 25 ⁇ M FeSO 4 and 100 ⁇ M L(+)-ascorbic acid followed by ⁇ 3 column volumes of 150 mM NaCl, 15 mM Tris.HCl pH 8.0 (metal ions might interfere with the ClyA recordings, unpublished results, thus excess of iron was avoided).
- AlkB-Fe ++ was subsequently eluted from the column in ⁇ 300 ⁇ l of elution buffer (150 mM NaCl, 15 mM Tris.HCl pH 8.0, 5 mM D-desthiobiotin (IBA)).
- bacterial pellets originating from 100 ml culture were resuspended in 30 ml lysis buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5, 1 mM MgCl 2 , 0.2 units/ml DNase, 10 ⁇ g/ml lysozyme) and incubated at RT for 20 min. Bacteria were further disrupted by probe sonication, and the crude lysate was clarified by centrifugation at 6000 ⁇ g at 4° C. for 30 min.
- lysis buffer 150 mM NaCl, 15 mM Tris.HCl pH 7.5, 1 mM MgCl 2 , 0.2 units/ml DNase, 10 ⁇ g/ml lysozyme
- the supernatant was allowed to bind to ⁇ 150 ⁇ l (bead volume) of Strep-Tactin® Sepharose® (IBA) pre-equilibrated with the wash buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5)—“end over end” mixing.
- the resin was then loaded on a column (Micro Bio Spin, Bio-Rad) and washed with ⁇ 20 column volumes of the wash buffer.
- DHFR n+ was subsequently eluted from the column in ⁇ 300 ⁇ l of elution buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5, 5 mM D-Desthiobiotin (IBA)).
- the concentration of DHFR n+ was measured using Bradford assay and the purity was checked using a 12% SDS-PAGE ( FIG. 12 ). Proteins were stored at 4° C. (up to 3 weeks) until use.
- E. Cloni® EXPRESS BL21 (DE3) cells were transformed with the pT7-SC1 plasmid containing the ClyA-AS gene.
- ClyA-AS contains eight mutations relative to the S. Typhi ClyA-WT: C87A, L99Q, E103G, F166Y, 1203V, C285S, K294R and H307Y (the H307Y mutation is in the C-terminal hexahistidine-tag added for purification).
- 18 Transformants were selected after overnight growth at 37° C. on LB agar plates supplemented with 100 mg/L ampicillin. The resulting colonies were inoculated into 2xYT medium containing 100 mg/L of ampicillin.
- the culture was grown at 37° C., with shaking at 200 rpm, until it reached an OD 600 of ⁇ 0.8.
- the expression of ClyA-AS was then induced by the addition of 0.5 mM IPTG and the growth was continued at 25° C.
- the pellets containing monomeric ClyA-AS were thawed and resuspended in 20 mL of wash buffer (10 mM imidazole, 150 mM NaCl, 15 mM Tris.HCl, pH 8.0), supplemented with 1 mM MgCl 2 and 0.05 units/mL of DNase I and the bacteria were lysed by sonication.
- wash buffer 10 mM imidazole, 150 mM NaCl, 15 mM Tris.HCl, pH 8.0
- 1 mM MgCl 2 0.05 units/mL of DNase I
- the crude lysates were clarified by centrifugation at 6000 ⁇ g for 20 min at 4° C. and the supernatant was mixed with 200 ⁇ L of Ni-NTA resin (Qiagen) in wash buffer.
- the resin was loaded into a column (Micro Bio Spin, Bio-Rad) and washed with ⁇ 5 ml of the wash buffer.
- ClyA-AS was eluted with approximately ⁇ 0.5 mL of wash buffer containing 300 mM imidazole. Protein concentration was determined by the Bradford assay. Because ClyA-AS monomers were not active upon freezing, they were stored at 4° C. until further use.
- Type I ClyA-AS oligomers were obtained by incubation of ClyA-AS monomers with 0.5% ⁇ -dodecylmaltoside (DDM, GLYCON Biochemicals, GmbH) at 25° C. for 15 min. ClyA-AS oligomers were separated from monomers by blue native polyacrylamide gel electrophoresis (BN-PAGE, Bio-rad) using 4-20% polyacrylamide gels. The bands corresponding to Type I ClyA-AS were excised from the gel and were placed in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 supplemented with 0.2% DDM and 10 mM EDTA to allow diffusion of the proteins out of the gel.
- DDM ⁇ -dodecylmaltoside
- the applied potential refers to the potential of the trans electrode.
- ClyA-AS nanopores were inserted into lipid bilayers from the cis compartment, which was connected to the ground electrode.
- the two compartments were separated by a 25 ⁇ m thick polytetrafluoroethylene film (Goodfellow Cambridge Limited) containing an orifice of ⁇ 100 ⁇ m in diameter.
- the aperture was pretreated with ⁇ 5 ⁇ l of 10% hexadecane in pentane and a bilayer was formed by the addition of ⁇ 10 ⁇ L of 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) in pentane (10 mg/mL) to both electrophysiology chambers.
- DPhPC 1,2-diphytanoyl-sn-glycero-3-phosphocholine
- oligomeric ClyA-AS was added to the cis compartment (0.5 mL) to obtain a single channel.
- ClyA-AS nanopores displayed a higher open pore current at positive than at negative applied potentials, which provided a useful tool to determine the orientation of the pore.
- Electrical recordings were carried out in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 (AlkB experiments) or 150 mM NaCl, 15 mM Tris.HCl pH 7.5 (DHFR experiments). The temperature of the recording chamber was maintained at 28° C. by water circulating through a metal case in direct contact with the bottom and sides of the chamber.
- I B and I O were determined from Gaussian fits to all point current histograms (0.05 pA bin size) for at least 15 individual protein blockades.
- ⁇ I RES % values were calculated from I RES % using propagation of errors. Current transitions from level 1 were analyzed with the “single-channel search” function in Clampfit. The detection threshold to collect the ligand-induced events for AlkB was set to 4 pA and events shorter than 10 ms were ignored.
- the detection threshold was also set to 4 pA and events shorter than 1 ms were neglected.
- the process of event collection was monitored manually.
- final values of ⁇ on and ⁇ off were based on average values derived from at least 3 single channel experiments at each concentration. Each experiment analysed more than 8 AlkB blockades.
- ligand-binding events At the low ligand concentrations (0.2 mM) about 100 ligand-binding events were measured. Otherwise more than 150 events were collected. In total, 500-1200 events were considered for 2-OG, 350-2100 events for SUC (350 events were collected at the lowest concentration, all other concentrations more than 800 events) and 500-1300 events for N-OG.
- DHFR tag :MTX >500 NADPH and >2000 NADP+ binding events were used in total to determine the values of ⁇ on and ⁇ off , where individual values for t on and t off were derived for at least five single channel experiments, each analysing more than 40 DHFR tag :MTX blockades and more than 2000 ligand-binding events.
- t off values could not be determined.
- t on values for NADPH were determined by collecting the times between the capture of the DHFR tag :MTX binary complex in the nanopore and the transition to the ⁇ 4 pA higher current level within the same blockade lasting longer than 0.2 s. Subsequently, the t on values were binned together as cumulative distributions and fitted to a single exponential fit to retrieve characteristic ⁇ on values. The values for k off represented in FIG. 2 b and FIG.
- Example 2 A Demethylase as a Protein Adaptor
- AlkB-Fe ++ co-oxidises methylated DNA and its cofactor 2-oxoglutarate (2-OG), producing succinate (SUC), carbon dioxide and formaldehyde (Aravind, L. & Koonin, E. V. (2001) Genome biol. 2, RESEARCH0007; Trewick, S. C.
- 2-oxoglutarate is an important metabolite that influences aging and age-related diseases (Chin, R. M. et al. (2014) Nature, 510, 397-401), and is a biomarker for non-alcoholic fatty liver disease (Rodriguez-Gallego, E. (2015) Int. j. obesity 39, 279-287), heart failure and cardiorenal syndrome (Nikolaidou, T. et al. (2010) Heart, 96, e14).
- the level of succinate in urine is a biomarker for kidney damage (Peti-Peterdi, J. (2014) U.S. Pat. No. 8,652,771).
- ClyA-AS Type I ClyA-AS
- I O ⁇ 1.7 ⁇ 0.1 nSi, average ⁇ SD
- N 38, ⁇ 60 mV, 28° C.
- N indicates the number of independent single nanopore experiments
- np the number of individual protein block-ades
- nl the total number of ligand binding events analysed.
- AlkB-Fe ++ -induced current blockades did not show ligand-induced transitions, suggesting that the trapped enzymes might have a preferred orientation inside the ClyA-AS lumen.
- An alternative explanation is that sub-populations of AlkB-Fe ++ might be inactive as a consequence of self-inactivation (Welford, R. W. et al. (2003) J Biol Chem 278, 10157-10161), proteolysis, loss of iron, misfolding, etc. AlkB blockades not showing ligand-induced current transitions were ignored and the enzyme was ejected from the pore by reversing the potential to +60 mV.
- AlkB-Fe ++ blockades were nearly eliminated upon addition of 40 ⁇ M of cognate aptamer ( FIG. 8 , Table 5), indicating that, as previously reported for other proteins [Soskine (2012) cited above], AlkB-Fe ++ formed complexes with the aptamer, which cannot be captured by ClyA nanopores as a result of electrostatic repulsion and/or steric hindrance (Franceschini, L. et al. (2013) Nat. Comm. 4, 2415). This suggests that the majority of captured AlkB proteins are natively folded, as such aptamer was evolved to bind to folded AlkB (Krylova, S. M. et al. (2011) Anal Biochem 414, 261-265).
- Example 3 A Reductase as a Protein Adaptor
- dihydrofolate is reduced to tetrahydrofolate and the cofactor NADPH is oxidised to NADP+.
- Tetrahydrofolate is a cofactor in many metabolic reactions, thus inhibitors of DHFR such as methotrexate (MTX) are antibiotic and anticancer agents.
- MTX methotrexate
- the ratio of the NADP+ and NADPH intracellular concentrations is used to monitor the oxidative stress in cells (Ogasawara, Y. et al. (2009) Biol . & pharmaceut. bull.
- DHFR tag a polypeptide tag containing four additional positive charges at the C-terminus of the protein
- DHFR tag a polypeptide tag containing four additional positive charges at the C-terminus of the protein
- NADPH added to the trans compartment also induced additional current enhancements to the binary complex blockades ( FIG. 4 a ).
- the binding of the two ligands to DHFR tag :MTX could be clearly differentiated ( FIG. 4 a ).
- ⁇ I RES % is the difference between the I RES % of the DHFR tag :MTX blockades and the I RES % induced by the ligand (L1B or L2B). 50 nM of DHFR tag and 400 nM MTX were added to the cis chamber, NADPH and NADP+ were added to the trans chamber.
- DHFR tag :MTX blockades Approximately 45% of the DHFR tag :MTX blockades did not respond to the addition of NADP+ (added in trans, FIG. 9 c,d ). Since all the observed DHFR tag molecules captured by ClyA-AS were bound to MTX, this effect is not likely due to misfolded DHFR molecules.
- DHFR tag :MTX blockades when NADPH was added to the trans chamber, two distinct populations of DHFR tag :MTX blockades were observed: the first ( ⁇ 55% of blockades) gave rise to NADPH binding events with a lifetime longer than the residence time of the complex within ClyA-AS (lifetime >3 seconds, “long” NADPH events), the second population ( ⁇ 45% of blockades) corresponded to DHFR tag :MTX blockades that displayed NADPH binding events with a lifetime of 38.5 ⁇ 0.8 ms (“short” NADPH events). Most blockades showed either “long” or “short” NADPH events ( FIG. 9 a ).
- DHFR construct consisted of DHFR from E. coli with the cysteine residues at positions 85 and 152 substituted with alanine and serine, respectively, and with a C-terminal Strep-tag, inserted for purification purposes, spaced by a 9 amino acid long linker (see later).
- the fusion tag polypeptide chain contained one additional net positive charge with respect to the wild type sequence (originating from the introduction of a Xho I restriction site in the DNA sequence of the protein).
- the addition of DHFR 50 nM, FIG.
- the sequence of the 10+ tag comprised of a S-tag (KETAAAKFERQHMDS) (SEQ ID NO:16) derived from pancreatic RNase A, followed by a positively charged coil (KIAALKQKIAALKYKNAALKKKIAALKQ, adapted from Ref. 40) (SEQ ID NO: 17) (Table 6) and, a Strep-tag for easy purification.
- DHFR and the three tags were spaced by flexible linkers ( FIG. 10 ). Since we could not predict what would be the effect of the positively charged tag and linker length on the DHFR blockades, we have also designed two constructs with shorter tags and smaller number of additional positive charges: DHFR 4+ and DHFR tag baring 4 and 5 net positive charges, respectively ( FIG. 10 ).
- DHFR 10+ , DHFR 4+ and DHFR tag induced fast current blockades to ClyA-AS nanopores that converted into second-long blockades upon binding to MTX ( FIG. 13 a -13 d ).
- DHFR 10+/4+/tag :MTX blockades were remarkably longer than DHFR:MTX blockades (e.g. the lifetime of DHFR tag :MTX blockades was ⁇ 1000 fold that of DHFR:MTX blockades), indicating that the positively charged tags efficiently counterbalanced the electrostatic and electrophoretic effects induced by MTX binding ( FIG. 13 a -13 d ).
- DHFR 10+/4+/tag :MTX complexes reported the binding of NADPH through ⁇ 4 pA enhancements of the residual ionic current ( FIG. 13 b -13 d , right)
- DHFR 10+ and DHFR 4+ blockades produced non-ideal output signals.
- the residual current of DHFR 10+ blockades often switched to a level of lower conductance ( FIG. 13 b , centre and right), while the binding of NADPH to DHFR 4+ :MTX prompted the quick release of the complex from the pore, indicating that 4 additional positive charges are not enough to keep ternary complex within the pore ( FIG. 13 c , right).
- DHFR tag :MTX:NADPH was internalised for sufficient time for accurate kinetic analysis and therefore it was chosen for thorough characterization as our nanopore-adaptor.
- Venus flytrap domain family of periplasmic binding proteins might provide ideal protein adaptors because: 1) they have a domain that has an elongated shape that appears to fit well inside the nanopore and provides a quiet blocked pore signal ( FIG. 14 ). 2) the domain comprises two lobes that upon binding close on the substrate through a large conformational change. 3) Periplasmic binding proteins (PBPs) scavenge or sense diverse nutrients in the environment by coupling to transporters in the inner cell membrane, thus they bind physiologically or technologically relevant substrates with high affinity and selectivity. 4) They bind hundreds of substrates and metabolites (B12 vitamin, many sugars, amino acids, neurotransmitters, etc). 5) Substrate binding appears to be modulated by an 8 residue motif, 15 thus targeted mutations might allow tuning the selectivity for target analytes to the experimental needs.
- ClyA-AS C87A/L99Q/E103G/F166Y/I203V/C285S/K294R/H307Y.
- Tris-HCl 150 mM NaCl and 15 mM Tris-HCl (pH 7.5)
- trans negative applied potentials
- the dissociation constant was determined by titrating the substrate and plotting the relative closed population (CL/(O+CL)), determined from the area of the all point current histogram, versus the concentration. Fitting this curve to a one-site binding isotherm gave a K d value of 0.47 ⁇ 0.03 ⁇ M ( FIG. 15C ), which is in agreement with previously described values obtained by smFRET and isothermal titration calorimetry (ITC) (Gouridis, G. et al. (2015) Nature struct . & mol. biol. 22, 57-64).
- the closing and opening rate constants were determined from the inverse of the open and closed state lifetimes respectively and were plotted versus the asparagine concentration.
- the opening rate constant did not show concentration dependency and the value of k opening was determined by the intercept at zero 9.4 s ⁇ 1 ( FIG. 15D ).
- glucose sensors should detect glucose concentrations between 1.65 and 22 mM (Yoo, E. H. & Lee, S. Y. (2010) Sensors 10, 4558-4576).
- the sensitivity of GBP for glucose is ⁇ 1000 fold higher, suggesting that in a few seconds a GBP-based sensor could measure the concentration of glucose in blood.
- glucose could be also measured in other body fluids such as saliva or sweat, where glucose concentration is much lower (8-210 ⁇ M 4 and 0.277-1.11 mM, respectively (Makaram, P. et al. (2014) Diagnostics 4, 27-46; Moyer, J. et al. (2012) Diabetes Technology & Therapeutics 14, 398-402).
- a device based on GBP would not require ‘finger pricking’.
- FIG. 19 Several mutations inside the CIYA-AS nanopore ( FIG. 19 ) were tested to find out which location within the nanopore allows better recognition.
- HT human thrombin
- FIG. 19B When added on the cis side of the nanopore, HT enters the pore and switches between L1 and L2 binidng sites ( FIG. 19B ).
- L2 At high applied potential L2 is populated more than L1 ( FIG. 19 c ).
- W tryptophan residue
- FIG. 19C The occupancy of L1 and L2 at different potentials depended on the mutant tested ( FIG. 19C ). Substitutions at position 49, 56 and 60 had the strongest effect, revealing the potential binding site for HT inside the nanopore.
Abstract
Description
- This application is a Continuation of U.S. application Ser. No. 15/566,577, filed Oct. 13, 2017, which is a national stage filing under 35 U.S.C. 371 of International Patent Application Serial No. PCT/EP2016/058252, filed Apr. 14, 2016. Foreign priority benefits are claimed under 35 U.S.C. § 119(a)-(d) or 35 U.S.C. § 365(b) of British application number 1507264.8, filed Apr. 29, 2015 and British application number 1506307.6, filed Apr. 14, 2015. The entire contents of each of these applications are incorporated herein by reference.
- This application includes an electronically submitted sequence listing in .txt format. The .txt file contains a sequence listing entitled “O036670098US01-SEQ-KZM” created on Sep. 27, 2021 and is 24,656 bytes in size. The sequence listing contained in this .txt file is part of the specification and is hereby incorporated by reference herein in its entirety.
- The present invention relates to nanopore sensors comprising nanopore proteins and protein adaptors internalized in the lumen of the nanopores. The protein adaptor retains both its binding specificity for specific substrates and its functional activity, so that the nanopore sensor may be used for detecting analytes and characterizing unique properties of bound analytes.
- Over the past two decades nanopore analysis has emerged as a promising analytical tool for single-molecule analysis [Howorka, S. & Siwy, Z. (2009) Chem Soc Rev 38, 2360-2384; Bayley, H. (2015) Clin. chem. 61, 25-31; Luchian, T et al. (2003) Angew. Chem. 42, 3766-3771; Bezrukov, S. M. et al. (1994) Nature 370, 279-281]. Nanopore technology allows the investigation of native molecules with high sampling bandwidth without the need for labelling, chemical modifications or surface immobilisation. Further, the ionic current output signal can be easily interfaced with miniaturised and portable electronic devices. For instance, arrays of nanopores integrated into a MinION™ sequencer have been recently used for the profiling of genomic DNA [Ashton, P. M. et al. (2014) Nat. Biotechnol. 33, 296-300; Mikheyev, A. S. & Tin, M. M. (2014) Mol. ecol. res. 14, 1097-1102; Quick, J. et al. (2014) GigaScience 3, 22.]. Furthermore, biological nanopores have been reconstituted into bilayers formed on glass nanopipettes (White, R. J. et al (2007). J Am Chem Soc 129, 11766-11775) and on glass tips for scanning ion-conductance microscopy (Zhou, Y. et al (2014) Langmuir 30, 15351-15355). Therefore, nanopore-functionalized nanopipettes that can detect and quantify metabolites are promising platforms for measurement in single cells.
- Previous studies showed that small molecules binding to cyclodextrin (Gu, L. Q. et al. (1999) Nature 398, 686-690) and cyclic peptide adaptors (Sanchez-Quesada, (2000) J. Am. Chem. Soc. 122, 11757-11766) or cucurbiturils carriers (Braha, O. et al. (2005) Chemphyschem, 6, 889-892). (“guest adaptors”) could be detected by ionic current recordings using the α-hemolysin (αHL) nanopore. However, these guest adaptors and carriers do not bind selectively to host molecules, complicating the identification of specific analytes, especially in a complex mixture of compounds like a biological sample. Thus, there remains a need in the art for new nanopore sensors that confer highly-selective binding to target analytes.
- It is well-known that proteins bind selectively to targets, and a further study demonstrated that electroosmotic and electrophoretic forces allow small proteins such as thrombin to become trapped inside nanopores [Soskine, M. et al. (2013) J Am Chem Soc, 135, 13456-13463; Soskine, M. (2012) Nano Lett. 12, 4895-4900], suggesting that proteins might be used as adaptors inside nanopores. However, building such hybrid devices is challenging. Most proteins are too large to be incorporated into the αHL and other biological nanopores [Jung, Y. et al. (2005) Biochem. 44, 8919-8929; Movileanu, L. (2000) Nat. Biotechnol. 18, 1091-1095. Fahie, M. et al. (2015) ACS nano, 9, 1089-1098] and translocate through solid-state nanopores too fast to be properly sampled (Plesa, C. et al. (2013) Nano Lett., 13, 658-663). Moreover, analysis in solid-state nanopores indicates that proteins would not be expected to retain their structure or function in the lumen of a nanopore. In solid-state nanopores, proteins are stretched by an electrical field (Oukhaled, A. et al. (2011) ACS
nano 5, 3628-3638) and unfolded under applied potentials higher than +200 mV (Freedman, K. J. (2013). J.Scientific reports 3, 1638). If proteins are stretched or unfolded, their target binding sites and function are likely lost. - Described herein is a nanopore sensor based on a nanopore and a protein adaptor that is internalized in the lumen of the nanopore. Different types of proteins, including enzymes, can be used. The protein adaptor remains in the lumen of the nanopore without the use of covalent chemistry or other immobilization techniques, and surprisingly, the protein adaptor retains its folded structure, function and/or binding properties. The binding of analytes to the internalized protein adaptor is reflected by changes in the nanopore conductance. Accordingly, methods for detecting analytes using the sensor are also described, and uses of the sensor in the discovery of new therapeutics and the detection of biomarker analytes in biological samples is disclosed.
- A first aspect of the present invention relates to a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, wherein the protein adaptor is a functional enzyme or ligand-binding protein.
- In some embodiments, a first opening in the nanopore has a wider diameter than a second opening in the nanopore.
- In certain embodiments, the nanopore sensor is cytolysin A (ClyA) or a mutant or variant thereof.
- In some embodiments, the protein adaptor is globular. The protein adaptor may be a functional enzyme selected from a demethylase and a reductase. In certain embodiments, the protein adaptor comprises a tag. The tag may have a net overall positive or negative charge.
- In certain embodiments, the protein adaptor forms a complex with one or more additional molecules. In some embodiments, the protein adaptor binds to a target analyte. The target analyte may be selected from a small molecule analyte, a protein analyte, and a nucleic acid analyte. In some embodiments, the target analyte is charged.
- In some embodiments, the nanopore sensor is ClyA, and comprises a plurality of subunits, each subunit comprising an amino acid sequence represented by SEQ ID NO:3.
- In certain embodiments, the nanopore sensor is a demethylase, for example, AlkB demethylase. In certain embodiments, the nanopore sensor is a reductase, for example, dihydrofolate reductase. In a specific embodiment the demethylase is AlkB demethylase comprising an Asn120Asp mutation.
- Another aspect of the present invention relates to methods for detecting an analyte in a sample, comprising the steps of:
-
- a) obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, wherein the protein adaptor is a functional enzyme or ligand-binding protein.
- b) adding a sample comprising an analyte to the cis side or the trans side of the nanopore, and
- c) measuring conductance across the nanopore, wherein a change in conductance after addition of the sample indicates the binding of the analyte to the protein adaptor and the presence of the analyte in the sample.
- The present invention thus discloses a method for detecting an analyte in a sample, comprising (a) obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, (b) adding the sample to the cis side or the trans side of the nanopore, and (c) measuring conductance across the nanopore, wherein a change in conductance after adding the sample indicates the analyte is present in the sample and has bound to the protein adaptor.
- The present invention thus discloses a method for identifying a ligand for a protein adaptor, comprising (a) obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, (b) adding a test compound to the cis side or the trans side of the nanopore, and (c) measuring the conductance across the nanopore, wherein a change in conductance after adding the test compound indicates that the test compound is a ligand that binds to the protein adaptor.
- Herein the nanopore has a first and a second opening whereby the first opening has a wider diameter than the second opening.
- In specific embodiments, the nanopore is cytolysin A (ClyA) or a mutant or variant thereof such as cytolysin A (ClyA) mutant Gln56Trp.
- In specific embodiments, ClyA comprises a plurality of subunits, each subunit comprising an amino acid sequence represented by SEQ ID NO:3.
- In specific embodiments, the protein adaptor is globular.
- In specific embodiments, wherein the protein adaptor is a demethylase enzyme or a reductase enzyme, such as AlkB demethylase (for example AlkB demethylase comprising an Asn120Asp mutation) or dihydrofolate reductase.
- In specific embodiments the protein adaptor comprises a tag, which may have a net overall positive or negative charge.
- In specific embodiments wherein the protein adaptor forms a complex with one or more additional molecules.
- In specific embodiments the analyte is a small molecule, a protein, or a nucleic acid. In specific embodiments the analyte is charged.
- Another aspect of the present invention is the use of a nanopore sensor as described above the detection of an analyte in a sample.
- In specific embodiments the analyte is a small molecule, a protein, or a nucleic acid.
- In specific embodiments, the analyte is charged.
-
FIGS. 1A-1C show internalization of AlkB-Fe++ into ClyA-AS.FIG. 1A shows a cartoon representation of E. coli AlkB (green) containing a metal ion (Co2+, sphere) and binding to the cofactor (2-OG, labeled). The DNA binding site is depicted by an orange line. PDB_ID 3KHB.FIG. 1B shows the representation of a single AlkB-Fe++ enzyme confined in a ClyA-AS nanopore (shown as cross-section) embedded in a planar lipid bilayer (labeled) under a negative applied potential. The dimensions of the pore consider the Van der Waals radii of the atoms.FIG. 1C , (top panel) shows typical current blockades provoked by AlkB-Fe++ molecules (˜4 nM, cis) entering a ClyA-AS nanopore at −60 mV. The open pore current (IO) is represented by a blue dashed line, whileLevel 1 andLevel 2 are shown by dashed lines, respectively. The asterisks represent the restoration of IO upon the exiting of AlkB-Fe++ from the pore. The bottom panel shows the detail of a single AlkB-Fe++ blockade, showingLevel 1 andLevel 2 current levels. The current traces were collected by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cut-off was digitally applied to the traces shown inFIG. 1C (bottom panel). All recordings were carried out in 150 mM NaCl, 15 mM Tris HCl pH 8.0, at 28° C., and the AlkB was added to the cis compartment. -
FIGS. 2A-2B show binding of ligands to AlkB-Fe++ confined inside ClyA-AS.FIG. 2A shows a typical ligand-induced blockades to individual AlkB-Fe++ enzymes confined inside ClyA-AS at −60 mV. The ligand used is shown on the right of the trace. The boundLevel 1 current levels (L1O, L1N, L1S) are represented by the lowermost dashed lines. The substrate concentration was 0.6 mM for 2-OG, 0.6 mM for N-OG and 2 mM for SUC binding to wild type AlkB-Fe++, and 7.2 mM for 2-OG binding to N120D-AlkB-Fe++.FIG. 2B (left panel) shows dissociation rate constants (koff) as a function of the ligand concentration at −60 mV; whileFIG. 2B (right panel) shows Event frequency (1/τon) as a function of the ligand concentration at −60 mV. 2-OG is shown in squares, SUC in circles and N-OG in triangles. All values for koff and f are based on >350 binding events in total collected from N>3 single channel experiments with each experiment typically analysing n>8 AlkB blockades. All current traces were collected by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cut-off was digitally applied to the current traces. All recordings were carried out in 150 mM NaCl, 15 mM Tris HCl pH 8.0, at 28° C., and the ligands were added to the cis compartment. Errors are given as standard deviations. -
FIGS. 3A-3C show DHFR as a protein adaptor.FIG. 3A is a cartoon representation of E. coli DHFR (labeled) with bound methotrexate (MTX, spheres) and NADPH (spheres), PDB_ID 1RH3.FIG. 3B shows a representation of a single DHFRtag enzyme in complex with MTX confined in a ClyA-AS nanopore (shown as cross-section) embedded in a planar lipid bilayer (labeled) under a negative applied potential. The positively charged polypeptide tag added at the C-terminus of DHFR is labeled.FIG. 3C shows typical current blockades provoked by the capture of DHFRtag:MTX complexes (20 nM DHFRtag, 400 nM MTX, cis) by the ClyA-AS nanopore at −90 mV. The open pore current (IO) is represented by the lowermost dashed line, while L1M and L2M are shown by the middle and uppermost dashed lines, respectively. Asterisks represent restoration of IO upon the exiting of DHFRtag:MTX from the pore. The current traces were collected in 150 mM NaCl, 15 mM Tris HCl pH 7.5, at 28° C. by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz. -
FIGS. 4A-4B show current enhancements upon ligand binding to DHFRtagFIG. 4A shows ligand-induced current enhancements to individual DHFRtag:MTX blockades at −90 mV. NADP+ and NADPH were added to the trans compartment after addition of 20 nM DHFRtag and 400 nM MTX to the cis compartment. From top to bottom: no ligand; 5.7 μM of NADP+; 0.7 μM of NADPH; 7.4 μM of NADP+ together with 0.7 μM of NADPH. Free and bound Level 1 (L1 and L1o) are shown by dashed lines. Asterisks represent restoration of IO upon the exit of DHFRtag:MTX from the pore. On the right of the current traces is the schematic representation of the interaction of DHFRtag with MTX, NADP+ or NADPH.FIG. 4B (top panel) shows dissociation rate constants (koff) as a function of the NADP+ concentration added to the trans compartment at −90 mV.FIG. 4B (bottom panel) shows event frequency (1/τon) as a function of the NADP+ concentration added to the trans compartment at −90 mV. Errors are shown as standard deviations. All values for koff and f are based on >2000 binding events in total collected from N>8 single channel experiments with each experiment typically analysing n>20 DHFRtag:MTX blockades. All current traces were collected by applying a Bessel-low pass filter with a 2 kHz cut-off and sampled at 10 kHz. An additional Bessel 8-pole filter with 50 Hz cut-off was digitally applied to the traces shown inFIG. 4A . All recordings were carried out in 150 mM NaCl, 15 mM Tris HCl pH 7.5, at 28° C. -
FIG. 5 shows 2-OG induced binding events to a single AlkB-Fe++ molecule. The current trace shows the capture of an AlkB-Fe++ molecule (arrow) previously added to the cis compartment followed by the addition of 2-OG to the cis compartment. Confined AlkB-Fe++ showed L1 and L2 current levels, while 2-OG binding induced L1B and L2B ionic current levels. (All current levels are labeled). The grey dashed line corresponds to the open pore current (IO). The trace was recorded at −60 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off. -
FIGS. 6A-6B show 2-OG induced current levels to AlkB-Fe++.FIG. 6A shows an extended current trace showing L1, L1B, L2 and L2B current levels induced by the binding of 2-OG to a single confined AlkB-Fe++. InFIG. 6B are selected traces showing the details of the ligand-induced current levels. Transitions were always from L1B to L2B or from L1 to L2, or from L2 to L1 or from L2B to L1B. Current traces were recorded in presence of 4.8 mM 2-OG at −60 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off. -
FIG. 7 shows NADP+ induced binding events to DHFRtag:MTX. The current trace shows DHFRtag:MTX (added to the cis compartment, 50 nM of DHFRtag and 400 nM MTX) blockades before (left) and after (right) the addition of 5.7 μM NADP+ (arrow) to the trans compartment. The binding of NADP+ results in reversible current enhancements from L1M (uppermost dashed line) to L1M:N+ (labeled). The grey dashed line (lowermost dashed line) corresponds to the open pore current (IO). The trace was recorded at −90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off. -
FIG. 8 shows the effect of the cognate Anti-AlkB aptamer on the AlkB-Fe++-induced current blockades. The addition of 40 μM cognate aptamer (TGCCTAGCGTTTCATTGTCCCTTCTTATTAGGTGATAATA, SEQ ID NO: 27, Table 5) reduced the frequency of the AlkB-Fe++ blockades to ClyA-AS caused by 21 nM AlkB_Fe++ due to electrostatic repulsion and/or steric hindrance between the AlkB:aptamer complexes and the negatively charged ClyA-AS lumen (Soskine, M. (2012) Nano Lett. 12, 4895-4900). The recordings were carried out in 150 mM NaCl, 15 mM Tris HCl pH 8.0 at 28° C. and −35 mV applied potential. -
FIGS. 9A-9D show heterogeneity of NADPH and NADP+ binding to DHFRtag:MTX. InFIGS. 9A and 9B , the current traces show the capture of DHFRtag:MTX inside ClyA-AS (50 nM of DHFRtag and 400 nM of MTX added to the cis compartment), after the addition of 0.74 μM NADPH to the trans compartment. The uppermost dashed line represents the DHFRtag:MTX L1M level. The asterisks indicate “short” (i.e. low affinity) NADPH binding events, while the solid lines indicate “long” (i.e. high affinity) NADPH induced binding events. The arrows show the capture of a new DHFRtag:MTX complex. The current trace in (FIG. 9A ) shows DHFRtag:MTX blockades displaying either “short” or “long” NADPH binding events. The current trace in (FIG. 9B ) shows the switching between “short” and “long” binding modes within the same DHFRtag:MTX blockade.FIGS. 9C and 9D show DHFRtag:MTX blockades (50 nM DHFRtag and 400 nM MTX in cis) after the addition of 5.7 μM NADP+ in trans. The dashed line represents the DHFRtag:MTX L1M level, the non-responsive state of the binary complex towards NADP+ is indicated by a solid line. The arrows indicate the capture of a new DHFRtag:MTX complex. The current trace in (FIG. 9C ) shows DHFRtag:MTX blockades that are either responsive or non-responsive towards NADP+ addition. The current trace in (FIG. 9D ) shows the switching between non-responsive and responsive states within the same DHFRtag:MTX blockade. The traces were recorded at −90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Bessel (8-pole) low-pass filter with 50 Hz cut-off. -
FIG. 10 shows sequences of the 1+, 4+, tag (5 positive charges) and 10+ fusions to the DHFR C-terminus. The C-terminus of DHFR, the sequences of the S-tag, the positive coil and the Strep-tag are colored green, gray, cyan and yellow, respectively. The sequences of the flexible linkers are underlined. The positively charged amino acids in the polypeptide tags are indicated by an asterisk (*) and the negatively charged amino acids by a minus sign (−). -
FIG. 11 shows the purity of the strep-tagged purified wild type AlkB-Fe++ assayed by a 12% SDS PAGE. In the left lane is a protein marker (Page Ruler Plus Prestained Protein Ladder, Thermo scientific); in the right lane is 5 μg of the purified AlkB-Fe++. -
FIG. 12 shows the purity of the strep-tagged purified DHFRn+ assayed by a 15% SDS PAGE. Inlane 1 is a protein marker (Page Ruler Plus Prestained Protein Ladder, Thermo scientific). Lanes 2-4 contain ˜5 μg each of purified DHFR (lane 2), DHFR4+ (lane 3), DHFRtag (lane 4) andlane 5 contains ˜10 μg of purified DHFR10+. -
FIGS. 13A-13D show DHFRn+, DHFRn+:MTX and DHFRn+:MTX:NADPH induced current blockades to ClyA-AS nanopores. Representative traces recorded in presence of ˜50 nM ofFIG. 13A : DHFR,FIG. 13B : DHFR10+,FIG. 13C : DHFR4+,FIG. 13D : DHFRtag added to the cis compartment. Every set of three panels shows DHFRn+ blockades recorded without ligands (left panel), after the addition of 400 nM MTX to the cis compartment (centre panel) and after further addition of 20 μM of NADPH in cis (FIG. 13A ) or 0.7 μM of NADPH to the trans compartment (FIGS. 13B, 13C, 13D ) (right panel). The arrows indicate NADPH binding events to the binary DHFRn+:MTX complexes. The asterisks indicate the transition of DHFR10+:MTX to a lower conductance level. Current traces were recorded at −90 mV applied potential in 150 mM NaCl, 15 mM Tris.HCl pH 7.5 at 28° C. using 2 kHz filtering and 10 kHz sampling rate, and filtered digitally with a Gaussian low-pass filter with 500 Hz cut-off. -
FIG. 14 SBD (substrate-binding domains) proteins with the ClyA nanopore. Left. Type I ClyA-AS nanopore embedded in the lipid bilayer. The dimensions of the ClyA nanopores are indicated considering the van der Waals radii of the atoms. Right. Upper part, surface representation of SBD1 in the open configuration (PDB ID=4LA9). Lower part, surface representation of SBD2 in the open (PDB ID=4KR5) and closed, Gln-bound (PDB ID=4KQP) configuration. The proteins are colored according to their “in vacuum” electrostatics (red for negative regions and blue for positive regions, Pymol). -
FIGS. 15A-15D show the capture of SBD1 in Type I ClyA-AS (FIG. 15A ) Typical ionic current blockades provoked by the capture of SBD1 (substrate-binding domain 1) (74 nM, cis) by the type I ClyA-AS nanopore at −60 mV. The open pore, Level I and Level II current levels are indicated. (FIG. 15B ) Detail of SBD1 current blockade before (upper part) and after addition of 0.40 μM asparagine (cis). The current traces were collected in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5 at 24° C. by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz. A post-acquisition Gaussian filter of 100 Hz was applied. (FIG. 15C ) Kd values of SBD1 (74 nM, cis) for asparagine, obtained from the open (Level I) and closed ligand-bound (Level II) populations at the indicated substrate concentrations. Experiments were performed at −60 mV. (FIG. 15D ) Opening (kopening) and closing (kclosing) rate constants of SBD1 determined from the transition rates of SBD1 molecules trapped in the nanopore at −60 mV as a function of asparagine concentration. The kclosing was obtained from the slope of the linear fit. -
FIGS. 16A-16C show capture of SBD2. (FIG. 16A ) Typical current blockade provoked by the capture of SBD2 (70 nM, cis) by the type I ClyA-AS nanopore at −100 mV before (left) and after addition of 0.40 μM glutamine cis. The current traces were collected in 150 mM NaCl, 15 mM Tris-HCl, pH 7.5 at 24° C. by applying a Bessel low-pass filter with a 2 kHz cutoff and sampled at 10 kHz. A post-aqcuisition Gaussian filter of 100 Hz was applied. (FIG. 16B ) Kd values of SBD2 (70 nM, cis) for glutamine, obtained from Level II (bound state), and level I and Level III at the indicated substrate concentrations. Experiments were performed at −100 mV. (FIG. 16C ) Opening (kopening) and closing (kclosing) rate constants of SBD2. -
FIG. 17 shows that inactive SBD2 does not bind to glutamine. Typical current blockade provoked by the capture of E417W-SBD2 (cis) by the type I ClyA-AS nanopore at −100 mV before (left) and after addition of 200 μM glutamine cis. Red asterisks represent the restoration of IO upon the exiting of SBD2_D417F from the pore. Level I and Level II transition most likely represent the entry of SBD2 into ClyA nanopores in two different configurations. -
FIGS. 18A-18C Glucose sensing with a venus flytrap protein domain.FIG. 18a ) Cut-through a ClyA nanopore containing a GBP.FIG. 18b ) Cartoon representation of the open (blue) and closed (orange) configuration of the venus flytrap domain of GBP.FIG. 18c ) Electrical recording of the GPB blocked current in the absence (top) and presence (middle and bottom) of increasing concentrations of glucose. -
FIGS. 19A-19C show protein recognition with ClyA variants. -
FIG. 19A ) Cut through a ClyA-AS nanopore showing the incorporation of HT. The protein lodges in two sites inside the nanopore which are called L1 and L2.FIG. 19B ) Ionic current blockades of HT inside ClyA-AS showing the movement of HT between L1 and L2 at −35 mV.FIG. 19C ) Percentage of L1 and L2 residence inside ClyA-AS for different ClyA-AS mutants. -
FIG. 20 Shows the effect of nanopore mutations on Human thrombin blockades. The figure indicate the blockades induced by human thrombin at −35, −50 and −80 mV (from top to bottom) to ClyA-AS-WT, CLyA-AS-125W and ClyA-AS-v60w (from left to right). The blockades induced by human thrombin are similar for ClyA-AS-WT and CLyA-AS-125W, and differ for ClyA-AS-v60w, indicating that thrombin binding site is close to theposition 60 inside the ClyA nanopore. -
FIGS. 21A-21B show analyte recognition with ClyA nanopores. -
FIG. 21A ) Binding of Glutamine to SBD2 inside a ClyA-AS nanopore. Level I and Level III correspond to the open SBD2 configuration (see word file), while Level II corresponds to the ligand bound configuration. -
FIG. 21B ) mutant screened showing the difference between level I, Level II and Level III (as residual current %). Q56W provides the better recognition. -
FIG. 22 shows SBD2 blockades to ClyA-AS-q56w. The signal due to the binding of glutamine to the internalized adaptor (level L2) is enhanced when compared to the signal measured for the ClyA-WT pore (FIGS. 21A-21B ) - Proteins have evolved to identify their ligands with high specificity in a sea of very similar chemical species. Accordingly, a nanopore which has incorporated protein adaptors in the lumen of the nanopore is well-suited for use in detecting ligand analytes. When the internalized protein adaptor binds to its target analyte, the conformational change in the protein adaptor and/or presence of the target analyte bound to the protein adaptor is measured as a change in nanopore conductance, for example, as an increase in the ionic current blockade events in the nanopore.
- Accordingly, one aspect of the present disclosure relates to nanopore sensors comprising a nanopore (also called “pore,” “pore protein,” or “nanopore protein”) and a protein adaptor (or “adaptor” or “internalized protein” or “protein”) which is fully or partially internalized (or “contained,” “incorporated,” “trapped,” “set,” “accommodated,” “residing,” “embedded,” or “confined”) within the lumen of the nanopore.
- Exemplary nanopores include, but are not limited to cytolysins, hemolysins, porins, DNA packaging protein, and motor proteins. In some embodiments, the nanopore is Phi29 (Wendell, D. et al. (2009) Nat. nanotech. 4, 765-772), pneumolysin (Gilbert, R. J. et al. (1999) Cell 97, 647-655), FhuA (Niedzwiecki D J et al. (2012) Biophys J. 103, 2115-2124) or a solid-state nanopores.
- In certain embodiments, the nanopore is a pore-forming cytotoxic protein, for example, a bacterial cytolysin. In certain embodiments, the nanopore is a cytolysin from a gram-negative bacteria such as Salmonella or Escherichia coli (E. coli). In some embodiments, the nanopore is Cytolysin A (ClyA) from Salmonella typhi (S. typhi) or Salmonella paratyphi (S. paratyphi). In some embodiments, the nanopore is a mutant or variant of ClyA, such as a modified variant of ClyA like ClyA-CS or ClyA-AS as described in WO2014153625.
- In certain embodiments, the nanopore is cylindrically shaped with at least 2 openings, for example, a cis opening and a trans opening. A first opening may have a larger diameter than a second opening in the nanopore. In some embodiments, the cis opening has a larger diameter than the trans opening. Thus, the “cis diameter” is wider than the “trans diameter.” Alternatively, the trans opening may have a larger diameter than the cis opening. Typically, a nanopore is an oligomeric structure comprising subunits (or “monomers”), and the size of the pore lumen depends on the number and/or composition of subunits in the oligomeric structure. In some embodiments, the nanopore may comprise at least 7 monomers, for example, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 monomer subunits. In some embodiments, the nanopore comprises at least 20 monomer subunits, for example, 20-25, 25-30, 35-40, or 45-50 subunits. In certain embodiments, the nanopore comprises 12 subunits. In further embodiments, the nanopore comprises 13 subunits, or 14 subunits. The subunits may preferentially assemble in 12 mers and/or 13 mers, depending on the amino acid sequence of the subunits.
- The nanopores comprise subunits which may be assembled into different oligomeric forms. Within a single nanopore (for example a ClyA nanopore), each of the subunits may be identical, or the subunits may be different, so that subunits in a pore may comprise sequences that differ from sequences of other polypeptide subunits in the same nanopore. In certain embodiments, nanopores as disclosed herein, such as ClyA nanopores or variants such as ClyA-CS and ClyA-AS, may form more than one subtype depending on subunit composition. For example, there may be at least 2 or 3 different subtypes of subunits in the nanopore, depending on the composition of the subunits. ClyA-AS [Mueller, M. et al. (2009) Nature, 459, 726-730; Soskine, M. et al. (2013) J Am Chem Soc, 135, 13456-13463] (SEQ ID NO:3) may be assembled into at least 3 oligomeric forms (Type I, Type II and Type III ClyA) (Soskine, M. et al. (2013) J Am Chem Soc, 135, 13456-13463) that are large enough to accommodate proteins or protein-DNA complexes (Van Meervelt, V. et al (2014) ACS nano, 8, 128262-12835). Any nanopore that is assembled from individual subunits may have different oligomeric forms, and the oligomeric forms may vary in properties such as size and voltage dependent opening and closing (gating) of the nanopore. Subtypes may be preferentially formed by subunits of a particular polypeptide sequence.
- In some embodiments, the nanopore is ClyA from Salmonella typhi and comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence at least 80% identical to SEQ ID NO: 1. In certain embodiments, the subunits are represented by an amino acid sequence at least 85% identical, 90% identical, 95% identical, 99% identical or 100% identical to SEQ ID NO:1. Identical may refer to amino acid identity, or may refer to structural and/or functional identity. Accordingly, one or more amino acids may be substituted, deleted, and/or added, as compared with SEQ ID NO:1. Modifications may alter the pore lumen in order to alter the size, binding properties, and/or structure of the pore. Modifications may also alter the ClyA nanopore outside of the lumen.
- In certain embodiments, the ClyA nanopore comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), and wherein exactly one Cys residue is substituted with Ser. The Cys residue may be Cys 87 and/or Cys 285 in SEQ ID NO:1. In some embodiments, the Cys residue is Cys285. The remaining amino acid residues may also be substituted, for example, with amino acids that share similar properties such as structure, charge, hydrophobicity, or hydrophilicity. In certain embodiments, substituted residues are one or more of L99, E103, F166, and K294. For example, the substituted residues may be one or more of L99Q, E103G, F166Y, and K294R. An exemplary subunit may comprise substitutions L99Q, E103G, F166Y, K294R, and C285S. Thus, each subunit may comprise a polypeptide represented by an amino acid sequence of SEQ ID NO:2. An exemplary ClyA nanopore comprising subunits in which exactly one Cys residue is substituted with Ser may be called ClyA-CS.
- Other ClyA mutants of the present invention are variants with a mutation at Ser110, Lys125, Val67, Val60, Gln56 or Arg49. Specific embodiments of such variants are Lys125Trp, Val60Trp and Gln56Trp.
- In some embodiments, the ClyA nanopore comprises a plurality of subunits, wherein each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), and wherein exactly one Cys residue is substituted with Ala. The cysteine residue may be Cys 87 or Cys 285 in SEQ ID NO:1. In some embodiments, each subunit comprises a polypeptide represented by an amino acid sequence of SEQ ID NO:1 (or a sequence that is at least 85%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:1), wherein one Cys residue is substituted with Ser and/or exactly one Cys residue is substituted with Ala. The cysteine residues may be Cys87 or Cys285 in SEQ ID NO:1. Other amino acid residues may be substituted, for example, with amino acids that share similar properties such as structure, charge, hydrophobicity, or hydrophilicity. In certain embodiments, substituted residues are one or more of L99, E103, F166, K294, L203 and H207. For example, the substituted residues may be L99Q, E103G, F166Y, K294R, L203V, and H207Y. An exemplary subunit may comprise L99Q, E103G, F166Y, K294R, L203V, and H207Y, and C285S. Accordingly, each subunit may comprise a polypeptide represented by an amino acid sequence of SEQ ID NO:3. An exemplary ClyA nanopore comprising subunits in which exactly one Cys residue is substituted with Ser and exactly one Cys residue is substituted with Ala may be called ClyA-AS.
- The present disclosure further relates to nucleic acids encoding the modified ClyA nanopores. In some embodiments, a nucleic acid encoding a modified ClyA nanopore is represented by a nucleotide sequence that is at least 80%, 90%, 95%, 96%, 96%, 98%, or 99% identical to SEQ ID NO:4. A nucleic acid may be represented by SEQ ID NO: 5 or SEQ ID NO:6. Nucleotide sequences may be codon optimized for expression in suitable hosts, for example, E. coli.
- In some embodiments, the lumen of the nanopore is large enough to accommodate a protein adaptor that is folded and is either (1) not bound or (2) bound to a target such as a specific target analyte. The protein adaptor may be complexed with one or more additional molecules such as a co-factor or substrate or inhibitor to form a protein adaptor complex (or “adaptor complex”). The protein adaptor may bind non-specifically and/or with low affinity to non-targets before binding with high affinity to its target, particularly if the non-targets are chemically similar to the target. In heterogeneous biological samples, the protein adaptor may be exposed to a variety of analytes that are not its target analyte. The protein adaptor may also undergo conformational changes within the lumen of the nanopore upon binding to its target analyte.
- In certain embodiments, the lumen of the nanopore is at least 3 nm in diameter, for example, the diameter may measure 3 nm, 3.5 nm, 4 nm, 4.5 nm, 5 nm, 5.5 nm, 6 nm, 6.5 nm, 7 nm, or greater. The cis diameter of the nanopore lumen may be at least 3.5 nm and/or the trans diameter of the nanopore may be at least 6 nm. In general, cis refers to the end of the modified pore to which an analyte is added, while trans refers to the end of the modified nanopore through which the analyte exits after translocating the length of the nanopore lumen. In artificial lipid bilayers, for example, the trans end of a pore may be inserted in the lipid bilayer, while the cis end of the nanopore remains on the same side of the lipid bilayer. Accordingly, the cis diameter of the nanopore is the diameter of the opening at the cis end of the nanopore, while the trans diameter of the nanopore is the diameter at the opening of the opposite trans end of the nanopore. An analyte may be added to either side of the nanopore, for example, an analyte may be added to the cis opening of the nanopore so that it transverses the nanopore and exits from the trans side. Alternatively, an analyte may be added to the trans side of the nanopore. Nanopores are typically arrayed in a membrane such as a lipid bilayer, across which a potential can be applied. In general, the applied potential across the membrane refers to the potential of the trans electrode. Nanopores may be inserted into lipid bilayers from the cis compartment, which are connected to a ground electrode.
- A variety of protein adaptors may be fully or partially incorporated in the lumen of nanopores to form the nanopore sensors. In some embodiments, the protein adaptors are globular proteins (also called “spheroproteins”). The protein adaptors may be roughly spherical and may form colloids in water. For example, the protein adaptors may be characterized by apolar (hydrophobic) amino acids that are bounded towards the molecule's interior while polar (hydrophilic) amino acids are bound outwards.
- In some embodiments, the protein adaptor is a single protein. In certain embodiments, the protein adaptor is a protein domains, oligomers, and/or fragment of a protein. The protein adaptor may also be a complex or combination of single proteins and/or fragments. In certain embodiments, the protein adaptor complex comprises a protein (or fragments or domains) complexed with a small analyte such as a small molecule and/or an inhibitor. In certain embodiments, the protein adaptor is a functional enzyme. In certain embodiments, the protein adaptor is a ligand-binding domain.
- The protein adaptor must have dimensions that fit into a nanopore, for example, the protein adaptor may have a diameter that is smaller than the cis-diameter of the nanopore but larger than the trans-diameter of the nanopore. In some exemplary nanopores, the cis-diameter is wider than the trans-diameter, so the protein adaptor may pass through the cis end of the nanopore but not through the trans end. The protein adaptor may remain internalized for at least 0.1-1 μs, 1-10 μs, or 10-100 μs. The cis-diameter of the nanopore may be at least 4.5 nm, 5.0 nm, 5.5 nm, 6.0 nm, 6.5 nm, or 7 nm, while the trans-diameter of the nanopore is at least 1.5 nm, 2.0 nm, 3.0 nm, 3.3 nm, 3.5 nm, or 4.0 nm. In certain embodiments, the cis-diameter of the nanopore is 5.5 nm and the trans-diameter of the nanopore is about 3.0 nm, for example 3.3 nm. A protein adaptor suitable for internalization in the nanopore may have an average diameter that is smaller than the cis-diameter of the nanopore (for example, smaller than 5.5 nm) but larger than the trans-diameter of the nanopore (for example, larger than 3.0 nm or 3.3 nm). Accordingly, such a protein adaptor added to the cis side of the nanopore would be able to enter the nanopore but would not exit from the trans side of the nanopore. Conversely, if the trans-diameter were larger than the cis-diameter, then a protein adaptor added to the trans side of the nanopore would enter through the trans-opening but would not exit from the cis-opening.
- The average diameter of the protein adaptor may be determined by examination of the crystal structure, if available, or by estimation based on measurements such as molecular weight. For example, a protein with a molecular weight of about 20 kDa may be expected to have an average diameter of less than 3.5 nm, while a protein with a molecular weight of about 25 kDa may be expected to have an average diameter of more than 3.5 nm.
- Nanopores typically have lumens that are either negatively or positively charged, as the charge is required for the electroosmotic flow of charged molecules (e.g., analytes) through the nanopore when an electric field is applied across the nanopore. For example, when a nanopore has a negatively-charged lumen and a negative potential is applied to one side of the nanopore (e.g., the trans side of the nanopore), then a positively charged molecule will pass freely through the nanopore from the cis end to the trans end. Accordingly, for nanopores with negatively-charged lumen, protein adaptors suitable for internalization in the nanopore may be positively- or negatively-charged. Charges are not limiting for the incorporation of the protein adaptor. For example, moderately negatively-charged molecules (pI>4-isoelectric point) can be incorporated.
- Some protein adaptors are either too small to remain internalized in the nanopore and/or have a charge is not suitable for entry into the nanopore (i.e., a nanopore has a negatively-charged lumen but the protein has a highly negative charge). For example, if a protein has an average diameter that is smaller than both diameters of the nanopore, the protein may not be expected to remain internalized in the nanopore lumen. A protein that has an average diameter of less than 3.5 nm would not be expected to remain internalized for longer than a few milliseconds in a nanopore whose cis diameter is about 6.5 nm and whose trans diameter is about 3.5 nm. In some embodiments, a protein adaptor is tagged in order to be internalized in the nanopore and/or to be retained in the lumen of the nanopore. The tag may be a charged tag. For example, a protein may have a positively-charged tag in order to be internalized in a negatively-charged nanopore. The tag may be attached covalently or by other chemical means, or the tag may be present as a fusion with the protein adaptor, for example, the protein adaptor and tag may have been genetically encoded. In some embodiments, a tag comprises at least 4, 5, 6, 7, 8, 9, or 10 positively charged amino acid residues. Tags may comprise positively charged coils, spacers (e.g., flexible linkers), and/or labels for purification (e.g., strep tags). In some embodiments, the presence of a tag increases the retention time of the tagged protein adaptor by 100-fold or 1000-fold. Accordingly, the tagged protein adaptor may remain internalized in the nanopore for seconds whereas the untagged protein adaptor alone would only be internalized for milliseconds.
- In some embodiments, the protein adaptor is an enzyme (also called an “enzyme adaptor”). The enzyme may be an oxidoreducase (Enzyme Commission (EC) 1), transferase (EC2), hydrolase (EC3), lyase (EC4), isomerase (EC5), or ligase (EC6). The enzyme may be selected from a demethylase or a reductase. In some embodiments, the enzyme is a demethylase. For example, the enzyme may be AlkB demethylase. In certain embodiments, the enzyme is a reductase, such as dihydrofolate reductase (DHFR). The protein adaptor may be complexed with a molecule such as a small molecule (e.g., co-factor, inhibitor, and/or any other small molecule that binds to the protein adaptor) to form an adaptor complex, and this adaptor complex may bind to a target analyte. For example, DHFR may be complexed with methotrexate (MTX) to form an adaptor complex.
- In some embodiments, the protein adaptor comprises protein subunits, fragments, and/or domains of proteins. A protein subunit, fragment, or domain may be suitable for internalization, or may be made suitable by adding tags to increase size and/or charge. A protein adaptor complex may comprise a protein subunit, fragment, or domain.
- Other exemplary protein adaptors include but are not limited to antibodies, nanobodies, artificially designed binding elements, ligand binding proteins (for example, venus fly trap domains), transcription factors, metal-binding proteins, intrinsically unfolded binders, and more.
- Uses of Nanopore Sensors
-
- (a) Detection and Identification of Analytes
- Any analyte (or “target,” “target analyte,” “ligand,” “substrate,” or “binding partner”) that binds to a protein adaptor may be detected using the nanopore sensors described herein. Analytes include small molecules, including organic and inorganic molecules, and biological molecules such as proteins and nucleic acids. Analytes may be charged or may be uncharged molecules. In some embodiments, the analytes detected by the nanopore sensors disclosed herein are charged molecules. The charged molecules may be proteins or small molecules.
- Analytes may be known targets of the protein adaptor, for example, if the nanopore is used to determine whether a known binding partner of the protein adaptor is present in a mixture. Alternatively, new binding partners for the protein adaptor may be identified, for example, by screening a library of compounds or molecules which were not previously known to bind to the protein adaptor.
- Accordingly, one aspect of the present invention relates to a method for detecting an analyte in a sample, comprising obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, adding the sample to the cis side or the trans side of the nanopore, and measuring conductance across the nanopore, wherein a change in conductance after adding the sample indicates that the analyte is present in the sample and has bound to the protein adaptor. In some embodiments, conductance is measured continuously before, during, and after addition of the analyte.
- A further aspect relates to a method for identifying a ligand for a protein adaptor, comprising obtaining a nanopore sensor comprising a nanopore and a protein adaptor internalized in the lumen of the nanopore, adding a test compound to the cis side or the trans side of the nanopore, and measuring the conductance across the nanopore, wherein a change in conductance after adding the test compound indicates that the test compound is a ligand that binds to the protein adaptor.
- In some embodiments, the change in conductance is a change in the current blockades (IB), i.e., residual currents calculated as a percentage of the open pore current (IRES %). Thus, binding of an analyte to the protein adaptor may cause an increase in current blockades. In some embodiments, the current blockade is decreased. In certain embodiments, the change in current conductance is a measurable change in the noise pattern.
- Conductance across the nanopore is sensitive and highly specific to the identity of the ligand that binds to the protein adaptor. Conductance measurements may be used to differentiate between two ligands that differ from one another by a single atom. For example, the binding of a protein adaptor (or adaptor complex) to a specific substrate has a different conductance than the binding of the protein adaptor (or adaptor complex) to the substrate that lacks a hydride ion. Thus, binding of an internalized protein to NADPH may be distinguished from binding of the internalized protein to NADP+.
- (b) Enzyme Binding and Activity
- A protein adaptors may be an enzyme (“enzyme adaptor,” “internalized enzyme,” or “enzyme”), and various aspects of enzyme binding, activity, and function may be studied using a nanopore sensor comprising a nanopore and an enzyme adaptor. A further aspect of the present disclosure relates to a method for measuring enzyme kinetics, comprising obtaining a nanopore sensor comprising a nanopore and an enzyme adaptor internalized in the lumen of the nanopore, adding a ligand to the cis side or the trans side of the nanopore, measuring a first conductance change across the nanopore which reflects binding of the ligand to the enzyme adaptor, and measuring additional conductance changes across the nanopore which reflect enzyme kinetics such as association and dissociation of the ligand and the enzyme adaptor. In some embodiments, the measurements are obtained continuously over time while the ligand concentration is varied (e.g., increased).
- In certain embodiments, the method further comprises increasing the applied potential across the nanopore until the ligand dissociates from the enzyme adaptor, and the dissociation is measured by a change in conductance (for example, a decrease or increase in IB). In certain embodiments, the method further comprises decreasing the applied potential across the nanopore until the ligand binds to the enzyme adaptor, and the binding is measured by a change in conductance (for example, an increase or decrease in IB). In some embodiments, dissociation rate constants (koff) is measured from the inverse of the dwell times of the ligand-binding events (1/τoff), and does not depend on the concentration of the ligand. In certain embodiments, the frequencies of the ligand-induced events (f=1/τon) increase linearly with the concentration of the ligand, from which slopes the association rate constants (kon) are calculated.
- Notably, the enzyme adaptor retains its structure, binding sites, and activity. The ligand of the enzyme adaptor may be a substrate for the enzyme. Thus, an additional aspect of the present disclosure relates to a method for measuring activity of an enzyme adaptor on a substrate, comprising obtaining a nanopore sensor comprising a nanopore and an enzyme adaptor internalized in the lumen of the nanopore, adding the substrate to the cis side or the trans side of the nanopore, and measuring conductance across the nanopore, wherein a change in conductance after adding the ligand indicates activity of the enzyme adaptor on the substrate. The activity may be binding, cleavage, conformational changes, and/or other changes mediated by enzymes acting on their substrate.
- In some embodiments, competitive binding between two substrates can be monitored by conductance changes as the substrates bind and dissociate with the enzyme adaptor.
- All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
- While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
- The invention is now illustrated with examples which disclose specific embodiments of the invention.
- Unless otherwise specified all chemicals were bought from Sigma-Aldrich. DNA was purchased from Integrated DNA Technologies (IDT), enzymes from Fermentas and lipids from Avanti Polar Lipids. Stocks of NADPH and NADP+ (prepared in 15 mM Tris.HCl pH 7.5 150 mM NaCl) were kept at −20° C. and defrosted for single use. All errors in this work are given as standard deviations. The standard deviations (SD) for the values calculated from linear fits (
FIG. 1e ,FIG. 2e ) were calculated from standard errors (SE) given by the fit by applying the formula SE=SD/√{square root over (N)} where N is the number of independent data points in the graph. - To allow cloning, a Nco I site (CCATGG) was introduced in the wild type AlkB from E. coli at the beginning of the gene (5′ end). To keep the gene in reading frame an additional two bases were inserted after the Nco I site, resulting in an additional alanine residue after the starting methionine. For purification purposes, at the C-terminus of AlkB, a strep-tag was attached via a flexible glycine-serine-alanine linker and the open reading frame was terminated by two consecutive stop codons, followed by a Hind III restriction site (3′ end). The attachment of the strep-tag was carried out in two consecutive PCR reactions. During the first PCR reaction, the AlkB gene was amplified directly from the genomic DNA of a single BL21(DE3) E. coli (Lucigen) colony using Phire Hot Start II DNA polymerase (Finnzymes), 6 μM fAlkB (Table 5) and AlkBr1 (Table 5) primers in a 50 μL reaction volume. The PCR reaction cycling protocol was as follows: pre-incubation step at 98° C. for 30 s and then 30 cycles of denaturation at 98° C. for 5 s and extension at 72° C. for 1 min. The amplified product was purified using QIAquick PCR Purification Kit (Qiagen) and served as a template for the second PCR reaction, which used ˜100 ng of the purified PCR product amplified by Phire Hot Start II DNA polymerase using 6 μM of fAlkB (Table 5) and AlkBr2 (Table 5) primers in 300 μL volume. The cycling protocol was the same as in the previous step. The resulting PCR product containing the strep-tagged AlkB gene was purified with QIAquick PCR Purification Kit (Qiagen) and digested with Nco I and Hind III (FastDigest, Fermentas). The gel purified insert (QIAquick Gel Extraction Kit, Qiagen) was cloned under control of the T7 promoter into the pT7-SC1 expression plasmid using sticky-end ligation (T4 ligase, Fermentas) via Nco I (5′) and Hind III (3′) sites. 0.6 μL of the ligation mixture was transformed into 50 μL of E. Cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were grown overnight at 37° C. on ampicillin (100 μg/ml) LB agar plates. The identity of the clones was confirmed by sequencing. The DNA and proteins sequences of strep-tagged AlkB are included in the sequence listing (see Table 6).
- The synthetic gene encoding for E. coli DHFR was made by GenScript. The wild-type gene was modified by the substitution of the two Cys residues at positions 85 and 152 with Ala and Ser respectively (referred to as DHFR throughout SI and main text). Those substitutions were shown to be functionally tolerated by DHFR (Plesa, C. et al. (2013) Nano Lett., 13, 658-663). Further, the DNA sequence encoding for Met-Ala-Ser-Ala was added at the beginning of the gene in order to introduce a Nco I restriction site. To facilitate construction steps, a Xho I restriction site was introduced between the C-terminal tags and DHFR.
- As a first step the DHFR10+ construct was built (
FIG. 10 , for DNA and protein sequence see below). 100 ng of the synthetic DHFR gene was amplified with 5 μM of DHf and DHr primers (Table 5) with Phire Hot Start II DNA polymerase (Finnzymes) in 400 μL final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1 min for 30 cycles). The synthetic fragment encoding for the 10+ tag (made by IDT, for sequence see below) was amplified as described above using Cof and Cor primers (Table 5). DHf and Cof primers contain sequences that are the reverse-complement of each other, introducing sequence overlap between DHFR and 10+ tag PCR products, necessary for the next step, where both PCR products (2 μg each, gel-purified, QIAquick Gel Extraction Kit, Qiagen) were assembled together using Phire Hot Start II DNA polymerase (Finnzymes) in 50 μL final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1 min for 7 cycles). ˜100 ng of the purified (QIAquick PCR Purification Kit (Qiagen)) assembly product was amplified with 5 μM of DHf and Cor primers (Table 5), using Phire Hot Start II DNA polymerase (Finnzymes) in 400 μL final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1 min for 30 cycles). PCR product encoding for the whole length DHFR10+ was purified using the QIAquick PCR Purification Kit (Qiagen) and digested with Nco I and Hind III (FastDigest, Fermentas). The resulting insert was gel purified and cloned under control of the T7 promoter into the pT7-SC1 expression plasmid [Miles, G. et al. (2001) Biochem. 40, 8514-8522] using sticky-end ligation (T4 ligase, Fermentas) via Nco I (5′) and Hind III (3′) sites. 0.6 μL of the ligation mixture was transformed into E. Cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were selected overnight at 37° C. on ampicillin (100 μg/ml) LB agar plates. The identity of the clones was confirmed by sequencing. The DNA and protein sequence of DHFR10+ is provided below with the 10+ tag sequence indicated by capital letters in the DNA sequence. - DHFR, DHFR4+ and DHFRtag constructs (
FIG. 10 ) were built by deleting parts of the 10+ tag via whole plasmid PCR amplification followed by Xho I digestion and unimolecular ligation as follows: ˜100 ng of the DHFR_10+ tag plasmid was amplified using 5 μM of dcr and delF (to produce DHFR), or 2dcF (DHFR4+) or dcf (DHFRtag) using Phire Hot Start II DNA polymerase (Finnzymes) in 100 μL final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1.5 min for 30 cycles, primer sequences see Table 5). PCR products were purified with QIAquick PCR Purification Kit (Qiagen), digested with Xho I (FastDigest, Fermentas) and ligated with T4 ligase (Fermentas). 0.6 μL of the ligation mixture was transformed into E. Cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were selected overnight at 37° C. on ampicillin (100 μg/ml) LB agar plates. The identity of the clones was confirmed by sequencing. - The AlkB gene was amplified using 120D (forward) and T7 terminator (reverse) primers (Table 5). The PCR conditions were: 0.3 mL final volume of PCR mix (150 μl of RED Taq ReadyMix, 6 μM of forward and reverse primers, ˜400 ng of template plasmid), cycled for 27 times (after a pre-incubation step at 95° C. for 3 min, a cycling protocol was then applied: denaturation at 95° C. for 15 s, annealing at 55° C. for 15 s, extension at 72° C. for 3 min). The resulting PCR product was gel purified (QIAquick Gel Extraction Kit, Qiagen) and cloned into a pT7 expression plasmid (pT7-SC1) by MEGAWHOP procedure [Miyazaki, K. (2011) Methods Enzymol 498, 399-406]: ˜500 ng of the purified PCR product was mixed with ˜300 ng of the WT AlkB circular DNA template and the amplification was carried out with Phire Hot Start II DNA polymerase (Finnzymes) in 50 μL final volume (pre-incubation at 98° C. for 30 s, then cycling: denaturation at 98° C. for 5 s, extension at 72° C. for 1.5 min for 30 cycles). The circular template was eliminated by incubation with Dpn I (1 FDU) for 2 hr at 37° C. 0.6 μL of the resulted mixture was transformed into 50 μL of E. Cloni® 10G cells (Lucigen) by electroporation. The transformed bacteria were grown overnight at 37° C. on ampicillin (100 μg/ml) LB agar plates. The identity of the clones was confirmed by sequencing.
- pT7-SC1 plasmids containing the strep-tagged AlkB gene were transformed into E. Cloni® EXPRESS BL21(DE3) cells (Lucigen). Transformants were selected on LB agar plates supplemented with 100 μg/ml ampicillin grown overnight at 37° C. The resulting colonies were grown at 37° C. (200 rpm shaking) in 2xYT medium supplemented with 100 μg/ml ampicillin until the O.D. at 600 nm was ˜0.8. The cultures were then supplemented with 25 μM FeSO4 and 100 μM L(+)-ascorbic acid (Merck) from fresh stock solutions (25 mM FeSO4 and 100 mM L(+)-ascorbic acid in ddH2O) and the protein expression was induced by supplementing with 0.5 mM IPTG. Bacteria were further grown overnight at 25° C., 200 rpm shaking. The next day the bacteria were harvested by centrifugation at 6000×g at 4° C. for 25 min. The resulting pellets were frozen at −80° C. until further use.
- AlkB-Fe++ was purified as following: bacterial pellets originating from 100 ml culture were resuspended in 30 ml lysis buffer (150 mM NaCl, 15 mM Tris.HCl pH 8.0, 1 mM MgCl2, 0.2 units/ml DNase, 10 μg/ml lysozyme) supplemented with 5 μl β-mercaptoethanol (Merck) and 25 μM FeSO4 and 100 μM L(+)-ascorbic acid, and incubated at RT for 20 min. Bacteria were further disrupted by probe sonication, and the crude lysate was clarified by centrifugation at 6000×g at 4° C. for 30 min. The supernatant was allowed to bind to ˜150 μl (bead volume) of Strep-Tactin® Sepharose® (IBA) pre-equilibrated with the wash buffer (150 mM NaCl, 15 mM Tris.HCl pH 8.0) supplemented with 25 μM FeSO4 and 100 μM L(+)-ascorbic acid, for 1 hr at 4° C. (“end over end” mixing). Then the resin was loaded on a column (Micro Bio Spin, Bio-Rad) and washed with ˜20 column volumes of the wash buffer supplemented with 25 μM FeSO4 and 100 μM L(+)-ascorbic acid followed by ˜3 column volumes of 150 mM NaCl, 15 mM Tris.HCl pH 8.0 (metal ions might interfere with the ClyA recordings, unpublished results, thus excess of iron was avoided). AlkB-Fe++ was subsequently eluted from the column in ˜300 μl of elution buffer (150 mM NaCl, 15 mM Tris.HCl pH 8.0, 5 mM D-desthiobiotin (IBA)). Purified AlkB-Fe++ remained active for weeks, in agreement with the fact that self-inactivation of AlkB requires the presence of 2-OG.32 The concentration of AlkB-Fe++ was measured using Bradford assay and the purity was checked using a 12% SDS-PAGE (
FIG. 11 ). - After transformation of pT7-SC1 plasmids containing the strep-tagged DHFRn+ gene into E. Cloni® EXPRESS BL21(DE3) cells (Lucigen), transformants were selected on LB agar plates supplemented with 100 μg/ml ampicillin after overnight growth at 37° C. The resulting colonies were grown at 37° C. (200 rpm shaking) in 2xYT medium supplemented with 100 μg/ml ampicillin until the O.D. at 600 was ˜0.8, after which DHFRn+ expression was induced by addition of 0.5 mM IPTG, and subsequent switching to 25° C. for overnight growth. The next day the bacteria were harvested by centrifugation at 6000×g at 4° C. for 25 min and the resulting pellets were frozen at −80° C. until further use.
- For purification, bacterial pellets originating from 100 ml culture were resuspended in 30 ml lysis buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5, 1 mM MgCl2, 0.2 units/ml DNase, 10 μg/ml lysozyme) and incubated at RT for 20 min. Bacteria were further disrupted by probe sonication, and the crude lysate was clarified by centrifugation at 6000×g at 4° C. for 30 min. The supernatant was allowed to bind to ˜150 μl (bead volume) of Strep-Tactin® Sepharose® (IBA) pre-equilibrated with the wash buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5)—“end over end” mixing. The resin was then loaded on a column (Micro Bio Spin, Bio-Rad) and washed with ˜20 column volumes of the wash buffer. DHFRn+ was subsequently eluted from the column in ˜300 μl of elution buffer (150 mM NaCl, 15 mM Tris.HCl pH 7.5, 5 mM D-Desthiobiotin (IBA)). The concentration of DHFRn+ was measured using Bradford assay and the purity was checked using a 12% SDS-PAGE (
FIG. 12 ). Proteins were stored at 4° C. (up to 3 weeks) until use. - E. Cloni® EXPRESS BL21 (DE3) cells were transformed with the pT7-SC1 plasmid containing the ClyA-AS gene. ClyA-AS contains eight mutations relative to the S. Typhi ClyA-WT: C87A, L99Q, E103G, F166Y, 1203V, C285S, K294R and H307Y (the H307Y mutation is in the C-terminal hexahistidine-tag added for purification).18 Transformants were selected after overnight growth at 37° C. on LB agar plates supplemented with 100 mg/L ampicillin. The resulting colonies were inoculated into 2xYT medium containing 100 mg/L of ampicillin. The culture was grown at 37° C., with shaking at 200 rpm, until it reached an OD600 of ˜0.8. The expression of ClyA-AS was then induced by the addition of 0.5 mM IPTG and the growth was continued at 25° C. The next day the bacteria were harvested by centrifugation at 6000×g for 25 min at 4° C. and the pellets were stored at −80° C.
- The pellets containing monomeric ClyA-AS were thawed and resuspended in 20 mL of wash buffer (10 mM imidazole, 150 mM NaCl, 15 mM Tris.HCl, pH 8.0), supplemented with 1 mM MgCl2 and 0.05 units/mL of DNase I and the bacteria were lysed by sonication. The crude lysates were clarified by centrifugation at 6000×g for 20 min at 4° C. and the supernatant was mixed with 200 μL of Ni-NTA resin (Qiagen) in wash buffer. After 1 hr, the resin was loaded into a column (Micro Bio Spin, Bio-Rad) and washed with ˜5 ml of the wash buffer. ClyA-AS was eluted with approximately ˜0.5 mL of wash buffer containing 300 mM imidazole. Protein concentration was determined by the Bradford assay. Because ClyA-AS monomers were not active upon freezing, they were stored at 4° C. until further use.
- Type I ClyA-AS oligomers were obtained by incubation of ClyA-AS monomers with 0.5% β-dodecylmaltoside (DDM, GLYCON Biochemicals, GmbH) at 25° C. for 15 min. ClyA-AS oligomers were separated from monomers by blue native polyacrylamide gel electrophoresis (BN-PAGE, Bio-rad) using 4-20% polyacrylamide gels. The bands corresponding to Type I ClyA-AS were excised from the gel and were placed in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 supplemented with 0.2% DDM and 10 mM EDTA to allow diffusion of the proteins out of the gel.
- The applied potential refers to the potential of the trans electrode. ClyA-AS nanopores were inserted into lipid bilayers from the cis compartment, which was connected to the ground electrode. The two compartments were separated by a 25 μm thick polytetrafluoroethylene film (Goodfellow Cambridge Limited) containing an orifice of ˜100 μm in diameter. The aperture was pretreated with ˜5 μl of 10% hexadecane in pentane and a bilayer was formed by the addition of ˜10 μL of 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) in pentane (10 mg/mL) to both electrophysiology chambers. Typically, the addition of 0.01-0.1 ng of oligomeric ClyA-AS to the cis compartment (0.5 mL) was sufficient to obtain a single channel. ClyA-AS nanopores displayed a higher open pore current at positive than at negative applied potentials, which provided a useful tool to determine the orientation of the pore. Electrical recordings were carried out in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 (AlkB experiments) or 150 mM NaCl, 15 mM Tris.HCl pH 7.5 (DHFR experiments). The temperature of the recording chamber was maintained at 28° C. by water circulating through a metal case in direct contact with the bottom and sides of the chamber.
- Electrical signals from planar bilayer recordings were amplified using an Axopatch 200B patch clamp amplifier (Axon Instruments) and digitized with a Digidata 1440 A/D converter (Axon Instruments). Data were recorded by using the Clampex 10.4 software (Molecular Devices) and the subsequent analysis was carried out with the Clampfit software (Molecular Devices). Electrical recordings were performed in 150 mM NaCl, 15 mM Tris.HCl pH 8.0 (AlkB) or pH 7.5 (DHFR) by applying a 2 kHz low-pass Bessel filter and a 10 kHz sampling rate. For further analysis traces were filtered digitally with a Bessel (8-pole) low-pass filter with a 50 Hz cut-off. Residual current values (IRES %) were calculated from blocked pore current values (IB) and open pore current values (IO) as IRES %=100*IB/IO. IB and IO were determined from Gaussian fits to all point current histograms (0.05 pA bin size) for at least 15 individual protein blockades. ΔIRES % values were calculated from IRES % using propagation of errors. Current transitions from
level 1 were analyzed with the “single-channel search” function in Clampfit. The detection threshold to collect the ligand-induced events for AlkB was set to 4 pA and events shorter than 10 ms were ignored. For NADP+ and “short” NADPH binding events to DHFRtag:MTX, the detection threshold was also set to 4 pA and events shorter than 1 ms were neglected. The resulting event dwell times (toff) and the time between events (ton) were binned together as cumulative distributions and fitted to a single exponential to retrieve the ligand-induced lifetimes (τoff) and the ligand-induced event frequencies (f=1/τon). The process of event collection was monitored manually. For AlkB, final values of τon and τoff were based on average values derived from at least 3 single channel experiments at each concentration. Each experiment analysed more than 8 AlkB blockades. At the low ligand concentrations (0.2 mM) about 100 ligand-binding events were measured. Otherwise more than 150 events were collected. In total, 500-1200 events were considered for 2-OG, 350-2100 events for SUC (350 events were collected at the lowest concentration, all other concentrations more than 800 events) and 500-1300 events for N-OG. For DHFRtag:MTX, >500 NADPH and >2000 NADP+ binding events were used in total to determine the values of τon and τoff, where individual values for ton and toff were derived for at least five single channel experiments, each analysing more than 40 DHFRtag:MTX blockades and more than 2000 ligand-binding events. Since the life time of the “long” NADPH binding events to DHFRtag:MTX binary complex exceeded the residence time of the binary complex in the ClyA-AS nanopore (the dissociation of “long” NADPH was only occasionally observed), toff values could not be determined. ton values for NADPH were determined by collecting the times between the capture of the DHFRtag:MTX binary complex in the nanopore and the transition to the ˜4 pA higher current level within the same blockade lasting longer than 0.2 s. Subsequently, the ton values were binned together as cumulative distributions and fitted to a single exponential fit to retrieve characteristic τon values. The values for koff represented inFIG. 2b andFIG. 4b were determined by taking the average±standard deviations of 1/toff of at least 3 single channel experiments. The values of the association rate constants (kon) were determined from the slope of the linear regression curves calculated from the dependency of the event frequencies (f=1/τon) on the ligand concentration (OriginLab,FIGS. 2b and 4b ). Graphs were made with Origin (OriginLab Corporation) or Clampfit software (Molecular Devices). - As a first model protein we selected E. coli AlkB demethylase (Mw=25 kDa), a globular protein that is expected to pass the cis entry of ClyA, but is too large to traverse the trans exit of the nanopore (
FIG. 1a,b ). In complex with iron ions (AlkB-Fe++) AlkB co-oxidises methylated DNA and its cofactor 2-oxoglutarate (2-OG), producing succinate (SUC), carbon dioxide and formaldehyde (Aravind, L. & Koonin, E. V. (2001) Genome biol. 2, RESEARCH0007; Trewick, S. C. (2002) Nature 419, 174-178), 2-oxoglutarate is an important metabolite that influences aging and age-related diseases (Chin, R. M. et al. (2014) Nature, 510, 397-401), and is a biomarker for non-alcoholic fatty liver disease (Rodriguez-Gallego, E. (2015) Int. j. obesity 39, 279-287), heart failure and cardiorenal syndrome (Nikolaidou, T. et al. (2010) Heart, 96, e14). The level of succinate in urine is a biomarker for kidney damage (Peti-Peterdi, J. (2014) U.S. Pat. No. 8,652,771). - Individual AlkB-Fe++ molecules were studied using Type I ClyA-AS (ClyA-AS hereafter). In 150 mM NaCl, 15 mM Tris HCl and pH 8.0 ClyA-AS formed nanopores with a steady open pore conductance (IO=−1.7±0.1 nSi, average±SD, N=38, −60 mV, 28° C.) under a wide range of applied potentials. Here and hereafter N indicates the number of independent single nanopore experiments, np the number of individual protein block-ades and nl the total number of ligand binding events analysed. The addition of AlkB-Fe++ (˜4 nM) to the cis side of ClyA-AS provoked current blockades (IB), quoted here as residual currents calculated as a percentage of the open pore current (IRES %), due to the electroosmotic confinement of AlkB-Fe++ between the wider cis entrance and the narrower trans exit of the protein nanopore (
FIG. 1b )18,20. Conveniently, AlkB-Fe++ remained trapped inside the nanopore for several minutes (FIG. 1c ). The signal induced by AlkB-Fe++ fluctuated between two distinctive current levels, L1 (IRES %=52.6±2.0%, n=15, N=7) and L2 (IRES %=39.0±1.0%, np=15, N=7,FIG. 1c ), possibly due to two residence sites for the protein within the lumen of the ClyA-AS nanopores (Soskine, M. (2012) Nano Lett. 12, 4895-4900). - At −60 mV the addition to the cis reservoir of the cofactor (2-OG), an isosteric inhibitor (N-oxalylglycine, N-OG) or the processed cofactor (SUC) induced reversible current enhancements within the AlkB-Fe++ blockades (ΔIRES %=+4.7±1.3%, +4.9±1.0 and +4.6±1.3, respectively, n=15 AlkB blockades with each AlkB blockade typically np>15, nl>75 ligand binding events, N>4,N>4 single channel experiments,
FIG. 2a ,FIGS. 5 and 6 , and Table 1) that showed a mean duration (τoff) of 1.7±0.5 s, 1.8±0.4 s and 61±11 ms, respectively (>4500 ligand binding events, N>8 single channel experiments, with each experiment typically analysing n>10 AlkB blockades). -
TABLE 1 IRES % values of AlkB-Fe++-induced current blockades. No ligand 2-OG SUC N-OG L1 L2 L1B L2B L1B L2B L1B L2B IRES % IRES % ΔIRES % ΔIRES % ΔIRES % ΔIRES % ΔIRES % ΔIRES % AlkB- 52.6 ± 2.0% 39.0 ± 1.02% ±4.7 ± 1.3% ±1.7 ± 1.2% ±4.6 ± 1.3% ±2.1 ± 1.0% ±4.9 ± 1.0% ±1.7 ± 1.0% Fe++ WT AlkB- 55.0 ± 1.1% 39.3 ± 1.24% / / / / / / Fe++ N120D All data were collected at −60 mV applied potential in 150 mM NaCl, 15 mM Tris•HCl pH 8.0 at 28° C. Values were calculated from 15 individual AlkB blockades. Errors are given as standard deviations. The ClyA-AS open-pore conductance (Io) was 1.7 ± 0.1 nSi (N = 38 single channels). ΔIRES % is the difference between the IRES % of the AlkB-Fe++ protein blockades and the IRES % induced by the ligand (L1B or L2B). Proteins and ligands were added to the cis chamber. - The current enhancements were also observed from the current level L2 (
FIG. 6 ). We hypothesised that such current events reflected the conformational changes occurring during the transition from the open conformation of the apo-enzyme to the closed state of the ligand-bound form of AlkB-Fe++ (FIG. 2a ) [Bleijlevens, B. et al. (2008) EMBO rep. 9, 872-877; Bleijlevens, B. et al. (2012) Biochem. 2012, 51, 3334-3341]. To confirm this hypothesis we tested an AlkB mutant where the asparagine atposition 120, which has been reported to be involved in the binding of 2-OG to AlkB, was substituted by aspartate (N120D). The addition of 7.2 mM of 2-OG did not induce current transitions to the N120D-AlkB-Fe++ blockades (N=4), suggesting that the affinity of this AlkB mutant for 2-OG is strongly reduced. As expected for a protein-ligand association process the dissociation rate constants (koff, Table 2), measured from the inverse of the dwell times of the ligand-binding events (1/τoff), did not depend on the concentration of the ligand, while the frequencies of the ligand-induced events (f=1/τon) increased linearly with the concentration of the three ligands, from which slopes the association rate constants (kon) could be calculated (FIG. 2b , Table 2) -
TABLE 2 Kinetic parameters for ligand binding to AlkB-Fe++. 2-OG SUC N-OG koff −60 mV (s−1) 0.66 ± 0.33 16.6 ± 2.6 0.57 ± 0.10 kon −60 mV (s−1M−1) 1.8 ± 0.3 × 103 9.2 ± 1.3 × 102 1.2 ± 0.3 × 103 All data were collected in 150 mM NaCl, 15 mM Tris•HCl pH 8.0 at 28° C. Errors are given as standard deviations. Proteins and ligands were added to the cis chamber. - About 30% of the AlkB-Fe++-induced current blockades did not show ligand-induced transitions, suggesting that the trapped enzymes might have a preferred orientation inside the ClyA-AS lumen. An alternative explanation is that sub-populations of AlkB-Fe++ might be inactive as a consequence of self-inactivation (Welford, R. W. et al. (2003) J Biol Chem 278, 10157-10161), proteolysis, loss of iron, misfolding, etc. AlkB blockades not showing ligand-induced current transitions were ignored and the enzyme was ejected from the pore by reversing the potential to +60 mV. The AlkB-Fe++ blockades were nearly eliminated upon addition of 40 μM of cognate aptamer (
FIG. 8 , Table 5), indicating that, as previously reported for other proteins [Soskine (2012) cited above], AlkB-Fe++ formed complexes with the aptamer, which cannot be captured by ClyA nanopores as a result of electrostatic repulsion and/or steric hindrance (Franceschini, L. et al. (2013) Nat. Comm. 4, 2415). This suggests that the majority of captured AlkB proteins are natively folded, as such aptamer was evolved to bind to folded AlkB (Krylova, S. M. et al. (2011) Anal Biochem 414, 261-265). - E. coli dihydrofolate reductase (DHFR, Mw=19 kDa) was selected as a second model protein adaptor (
FIGS. 3a-3b ). During the DHFR catalytic cycle dihydrofolate is reduced to tetrahydrofolate and the cofactor NADPH is oxidised to NADP+. Tetrahydrofolate is a cofactor in many metabolic reactions, thus inhibitors of DHFR such as methotrexate (MTX) are antibiotic and anticancer agents. The ratio of the NADP+ and NADPH intracellular concentrations is used to monitor the oxidative stress in cells (Ogasawara, Y. et al. (2009) Biol. & pharmaceut. bull. 32, 1819-1823). We found that apo-DHFR, which is smaller than AlkB, dwelled inde ClyA-AS only for a few milliseconds. Upon the addition of MTX to the cis solution the frequency and the dwell time of the protein blockades decreased, while the residual current increased. The blockades were then abolished by the subsequent addition of NADPH to the same side (FIG. 13a-13d ). Since both the inhibitor and the cofactor are negatively charged, these results suggested that the additional negative charges increased the electrophoretic/electrostatic drag force opposing DHFR entry and residence inside the nanopore. In order to increase the residence time of the protein, we engineered DHFR by introducing a polypeptide tag containing four additional positive charges at the C-terminus of the protein (DHFRtag,FIG. 10 ). In complex with MTX, DHFRtag, added to the cis compartment, induced current blockades with a mean dwell of 3.1±1.4 s (N=5, np=230,FIG. 3c ) that was three orders of magnitude longer than DHFRtag or DHFR:MTX blockades mean dwell times. A possible explanation to this result is that, tuned by the additional positive charges, the binary DHFRtag:MTX complex is at a potential minimum inside the nanopore where the electroosmotic, electrophoretic and electrostatic forces are balanced. The dissociation of MTX from the binary complex was slower than the residence time of the complex inside the nanopore and could not be observed by ionic current recordings. As shown before with apo-AlkB-Fe++, DHFRtag:MTX blockades showed a main current level L1 (L1M, IRES %=74.7±0.5%, np=25, N=5) that rarely visited a second current level L2 (L2M, IRES %, =53.5±0.9%, np=25, N=5,FIG. 3c ). - At −90 mV the addition of the oxidised cofactor NADP+ to the trans compartment of ClyA-AS produced reversible current enhancements to the DHFRtag:MTX complex blockades formed in the cis solution (L1M:N+, ΔIRES %=+2.3±0.5%, np=15 blockades, nl>225, N=3; and τM:N+=102±11 ms, nl=19,000, N=9 np>800,
FIG. 4a , Table 3,FIG. 7 ). Association and dissociation rate constants could be measured from titration experiments (FIG. 4b , Table 4). - NADPH added to the trans compartment also induced additional current enhancements to the binary complex blockades (
FIG. 4a ). Remarkably, the current events induced by NADPH showed a slightly higher residual current (L1M:NH, ΔIRES %=+2.7±0.7%, np=15 nl=15, N=4, Table 3) than the NADP+ blockades (ΔIRES %=+2.3±0.5%) and had a dwell time longer than the residence time of the ternary complex inside the nanopore (FIG. 4a ). As a consequence, despite the minute difference between NADPH and NADP+ (a hydride ion), the binding of the two ligands to DHFRtag:MTX could be clearly differentiated (FIG. 4a ). -
TABLE 3 IRES % values of DHFRtag:MTX ligand-induced current blockades. No ligand NADP+ NADPH L1 L2 L1B L2B L2B L2B IRES % IRES % ΔIRES % ΔIRES % ΔIRES % ΔIRES % DHFRtag:MTX 74.7 ± 0.5% 53.5 ± 0.9% + 2.3 ± 0.5% +4.7 ± 0.9% +2.7 ± 0.7% + 5.4 ± 1.0% All data were collected at −90 mV applied potential in 150 mM NaCl, 15 mM Tris•HCl pH 7.5 at 28° C. Values were calculated from at least 15 individual DHFRtag:MTX blockades. Errors are given as standard deviations. The ClyA-AS open-pore conductance (Io) was 1.6 ± 0.1 nSi (N = 15 single channels). ΔIRES % is the difference between the IRES % of the DHFRtag:MTX blockades and the IRES % induced by the ligand (L1B or L2B). 50 nM of DHFRtag and 400 nM MTX were added to the cis chamber, NADPH and NADP+ were added to the trans chamber. -
TABLE 4 Kinetic parameters for ligand binding to DHFRtag:MTX. NADP+ NADPH koff,−90 mV (s−1) 10 ± 1 NA kon,−90 mV (s−1M−1) 2.1 ± 0.3 × 106 4.8 ± 1.2 × 106 All data were collected in 150 mM NaCl, 15 mM Tris•HCl pH 7.5 at 28° C. Errors are given as standard deviations. 50 nM of DHFRtag and 400 nM MTX were added to the cis chamber, NADPH and NADP+ were added to the trans chamber. - Although the bulk kinetic constants for the binding of NADP+ and NADPH to MTX:DHFR could not be retrieved from the literature, the equilibrium dissociation constant for the binding of 2-OG to AlkB-Mn++ was recently measured by an intrinsic tryptophan fluorescence quenching assay (KD bulk=4.1±0.6 10−6 M at 24° C.) (Ergel, B. et al. (2014) J biol chem 289, 29584-29601). By comparison, the equilibrium dissociation constant of 2-OG for AlkB-Fe++ inside the nanopore measured from the ratio of the association and dissociation constants (KD pore=koff/kon) was about two orders of magnitude higher than the bulk value (KD pore=3.7±1.9 10−4 M, −60 mV, 28° C.). This effect is likely to be related to the confinement of AlkB-Fe++ inside the nanopore and to the effect of the applied potential. ClyA nanopores have a negatively charged interior and are, therefore, cation selective (Ludwig, A. et al. (1999) Mol. Microbiol. 31, 557-567). Thus, under negative applied potentials (trans) the diffusion of the negatively charged ligands added to the cis solution through the nanopore is likely to be opposed. This is probably to be further accentuated by the unfavourable electrostatic interaction between the ligands and the wall of the nanopore lumen. This complication might be overcome by using nanopores with an internal charge with an opposite sign to
- Approximately 45% of the DHFRtag:MTX blockades did not respond to the addition of NADP+ (added in trans,
FIG. 9c,d ). Since all the observed DHFRtag molecules captured by ClyA-AS were bound to MTX, this effect is not likely due to misfolded DHFR molecules. Besides, when NADPH was added to the trans chamber, two distinct populations of DHFRtag:MTX blockades were observed: the first (˜55% of blockades) gave rise to NADPH binding events with a lifetime longer than the residence time of the complex within ClyA-AS (lifetime >3 seconds, “long” NADPH events), the second population (˜45% of blockades) corresponded to DHFRtag:MTX blockades that displayed NADPH binding events with a lifetime of 38.5±0.8 ms (“short” NADPH events). Most blockades showed either “long” or “short” NADPH events (FIG. 9a ). Rarely, however, the same DHFRtag:MTX blockade switched between the two NADPH binding behaviours (FIG. 9b ). “Long” and “short” NADPH events showed similar association rate constants (kon=4.8±1.2 s−1 μM−1 and kon=5.8±1.2 s−1 μM−1, respectively) and similar ΔIRES % values (2.7±0.7% and 2.2±0.9%, respectively,FIG. 9a,b ). Although “short” NADPH binding events could arise from NADP+ contaminations, this is unlikely since fresh NADPH aliquots (>95% purity) were used for every experiment. Furthermore, the lifetime of “short” NADPH events was significantly shorter than the lifetime of NADP+ events. In addition, the fact that most of the DHFRtag:MTX blockades showed only one binding behaviour, suggests that the observed heterogeneity is not arising from impurities in the substrate samples but from heterogeneity in the protein adaptor (FIG. 9 ). This variability in binding behaviour could then arise from different configurations of DHFRtag:MTX inside the ClyA-AS nanopore and/or from different conformations of the DHFRtag:MTX complex. Although the first hypothesis cannot be easily tested, it is interesting to note that previous studies revealed that MTX can bind to two different DHFR conformations with different binding affinities towards NADP+ and NADPH (Rajagopalan, P. T. et al. (2002) Proc Natl Acad Sci USA 99, 13481-13486). - Our initial DHFR construct consisted of DHFR from E. coli with the cysteine residues at positions 85 and 152 substituted with alanine and serine, respectively, and with a C-terminal Strep-tag, inserted for purification purposes, spaced by a 9 amino acid long linker (see later). The fusion tag polypeptide chain contained one additional net positive charge with respect to the wild type sequence (originating from the introduction of a Xho I restriction site in the DNA sequence of the protein). The addition of DHFR (50 nM,
FIG. 10 ) to the cis compartment induced transient blockades to the ClyA-AS open pore current with IRES % of 71.5±0.8% and a lifetime of 21±2 ms (n=200 blockades, N=4 single channels) under −90 mV applied potential (FIG. 13a , left). Subsequent addition of 400 nM of MTX to the cis compartment resulted in blockades with increased IRES % values (IRES %=78.4±0.6%) and decreased lifetime (3.3±0.7 ms, n=300 blockades, N=3 single channels,FIG. 13a , centre). Further addition of 20 μM NADPH to the same compartment resulted in the nearly total elimination of the DHFR blockades (FIG. 13a , right), suggesting that the DHFR:MTX:NADPH complex was mostly excluded from the ClyA-AS nanopore. Thus, although we could observe the interaction between the ligands and DHFR, the protein did not remain inside the ClyA-AS nanopore for a time long enough to determine the binding kinetics, prompting us to design DHFR constructs that would have a longer residence time within the ClyA-AS nanopore. - In order to increase the residence time of DHFR into ClyA, we have designed and tested three DHFR constructs that were decorated with a different number of positive charges incorporated into flexible C-terminal fusion tags. We expected the additional charges would prolong the dwell times of the ternary complex within the ClyA-AS nanopore because of the decreased electrostatic repulsion between the negatively charged protein (the pI of DHFR is 4.8) and the negatively charged nanopore lumen (Soskine (2013), cited above), and the reduced electrophoretic drag on DHFR under negative applied potentials. Initially we tested DHFR10+, which consisted of the DHFR gene with a C-terminal recombinant tag baring 10 net positive charges with respect to wild type DHFR. The sequence of the 10+ tag comprised of a S-tag (KETAAAKFERQHMDS) (SEQ ID NO:16) derived from pancreatic RNase A, followed by a positively charged coil (KIAALKQKIAALKYKNAALKKKIAALKQ, adapted from Ref. 40) (SEQ ID NO: 17) (Table 6) and, a Strep-tag for easy purification. DHFR and the three tags were spaced by flexible linkers (
FIG. 10 ). Since we could not predict what would be the effect of the positively charged tag and linker length on the DHFR blockades, we have also designed two constructs with shorter tags and smaller number of additional positive charges: DHFR4+ and DHFRtag baring 4 and 5 net positive charges, respectively (FIG. 10 ). - DHFR10+, DHFR4+ and DHFRtag induced fast current blockades to ClyA-AS nanopores that converted into second-long blockades upon binding to MTX (
FIG. 13a-13d ). DHFR10+/4+/tag:MTX blockades were remarkably longer than DHFR:MTX blockades (e.g. the lifetime of DHFRtag:MTX blockades was ˜1000 fold that of DHFR:MTX blockades), indicating that the positively charged tags efficiently counterbalanced the electrostatic and electrophoretic effects induced by MTX binding (FIG. 13a-13d ). Although the blockades induced by the DHFR10+/4+/tag:MTX complexes reported the binding of NADPH through ˜4 pA enhancements of the residual ionic current (FIG. 13b-13d , right), DHFR10+ and DHFR4+ blockades produced non-ideal output signals. The residual current of DHFR10+ blockades often switched to a level of lower conductance (FIG. 13b , centre and right), while the binding of NADPH to DHFR4+:MTX prompted the quick release of the complex from the pore, indicating that 4 additional positive charges are not enough to keep ternary complex within the pore (FIG. 13c , right). On the other hand, DHFRtag:MTX:NADPH was internalised for sufficient time for accurate kinetic analysis and therefore it was chosen for thorough characterization as our nanopore-adaptor. - Example 5 Detection of Analytes with Venus Flytrap Domains
- Venus flytrap domain family of periplasmic binding proteins (PBP) might provide ideal protein adaptors because: 1) they have a domain that has an elongated shape that appears to fit well inside the nanopore and provides a quiet blocked pore signal (
FIG. 14 ). 2) the domain comprises two lobes that upon binding close on the substrate through a large conformational change. 3) Periplasmic binding proteins (PBPs) scavenge or sense diverse nutrients in the environment by coupling to transporters in the inner cell membrane, thus they bind physiologically or technologically relevant substrates with high affinity and selectivity. 4) They bind hundreds of substrates and metabolites (B12 vitamin, many sugars, amino acids, neurotransmitters, etc). 5) Substrate binding appears to be modulated by an 8 residue motif, 15 thus targeted mutations might allow tuning the selectivity for target analytes to the experimental needs. - The interaction of SBD1 with asparagine was sampled using type I ClyA-AS nanopores. ClyA-AS (C87A/L99Q/E103G/F166Y/I203V/C285S/K294R/H307Y). In 150 mM NaCl and 15 mM Tris-HCl (pH 7.5), the addition of 74 nM of SBD1 to the cis compartment of Type I ClyA-AS induced transient current blockades at negative applied potentials (trans). At −60 mV the blockades showed one main level (Level I,
FIG. 15A ,B) with a residual current (Ires %=IB/I0×100) of Ires %=67.6±0.1% (N=5). Every 3.5±0.1 s−1 (mean±S.E., n=212) the current switched to Level II (Ires %=66.8±0.4%, N=5) with a lifetime of 109±1 ms (mean±S.E., n=340). The protein blockades released spontaneously after 4.2±1.8 s (mean±S.E., n=291). Upon addition of asparagine (concentrations ranging from 200 nM to 4 μM,FIG. 15B ), the frequency of the level II increased (FIG. 15B ), suggesting that the current blockades are due to the binding of arginine to the SBD1 adaptor inside the nanopore. An inactive SBD1 variant, containing the mutation E184W showed similar blockades to Type I ClyA-AS pores at −60 mV (Ires %=66.7). However, addition of up to 1 mM asparagine did not show any Level II blockades, indicating that Level II blockades confirming to the asparagine-bound or closed conformation of SBD1. - The dissociation constant was determined by titrating the substrate and plotting the relative closed population (CL/(O+CL)), determined from the area of the all point current histogram, versus the concentration. Fitting this curve to a one-site binding isotherm gave a Kd value of 0.47±0.03 μM (
FIG. 15C ), which is in agreement with previously described values obtained by smFRET and isothermal titration calorimetry (ITC) (Gouridis, G. et al. (2015) Nature struct. & mol. biol. 22, 57-64). The closing and opening rate constants were determined from the inverse of the open and closed state lifetimes respectively and were plotted versus the asparagine concentration. The closing rate was linearly dependent on the substrate concentration and the slope of the linear fit gave the kclosing=1.2×107 s−1 M−1. The opening rate constant did not show concentration dependency and the value of kopening was determined by the intercept at zero 9.4 s−1 (FIG. 15D ). - The interaction of SBD2 with glutamine was sampled using type I ClyA-AS nanopores at −100 mV. The addition of 72 nM of SBD2 induced a current blockade that fluctuated between two levels I (Ires %=63.6±0.3%, τ=256±5 ms, N=3) and level III (Ires %=61.0±0.2%, τ=145±13 ms, N=3). Protein blockades remained inside the nanopore for 3.9±0.7 s (mean±S.E., n=225). Rarely the current visited an additional ionic current level, Level II (Ires %=62.5±0.3%, τ=18±1 ms, n=856, N=3).
- We studied ligand binding by stepwise addition of glutamine at concentrations ranging from 200 nM to 3 μM. After addition of glutamine, the frequency of level II increased linearly with the concentration of glutamine, suggesting this level is the glutamine-bound state. Addition of up to 200 μM glutamine to the SBD2(D417F), a variant that cannot close, did not show any Level II blockades; although conversion between Level I and Level II were still observed (
FIG. 17A ). These results further suggests that Level II corresponds to the glutamine-bound (FIG. 16A ), while the levels I and III might represent different configurations of the protein inside the nanopore. Binding rates were determined from the lifetimes as described above. Upon linear fitting of the binding rate curve the glutamine binding rates from Level I and III were determined. Glutamine binding from Level I showed a nearly identical on rate (kon=3.7×107 s−1 M−1) as binding from Level II (kon=3.8×107 s−1 M−1,FIG. 3C ). The opening rate constant was determined by the intercept at zero koff=39.7 s1. The obtained Kd value of glutamine binding to SBD2 (1.27±0.14 μM,FIG. 16B ) is in agreement with previously described values obtained by smFRET and ITC (Gouridis, G. et al. (2015) Nature struct. & mol. biol. 22, 57-64). - Preliminary results showed that the venus flytrap domain of a glucose binding protein (GBP) from E. coli might be a good protein adaptor for a glucose sensor. GBP showed a low background signal (
FIG. 18 ) and an average residence time of ˜2 s. Interestingly, in the absence of ligand we observed two current levels, which probably reflected the open and closed conformation of the protein (FIG. 18b-c ). The addition of glucose to the cis solution increased the dwell time of one level (presumably the closed state,FIG. 18 ), suggesting that the conformational changes associated with the binding of ligands to the nanopore can be observed. According to the U.S.FDA recommendations, glucose sensors should detect glucose concentrations between 1.65 and 22 mM (Yoo, E. H. & Lee, S. Y. (2010)Sensors 10, 4558-4576). The sensitivity of GBP for glucose is ˜1000 fold higher, suggesting that in a few seconds a GBP-based sensor could measure the concentration of glucose in blood. Further, glucose could be also measured in other body fluids such as saliva or sweat, where glucose concentration is much lower (8-210 μM4 and 0.277-1.11 mM, respectively (Makaram, P. et al. (2014)Diagnostics 4, 27-46; Moyer, J. et al. (2012) Diabetes Technology &Therapeutics 14, 398-402). A device based on GBP would not require ‘finger pricking’. - Several mutations inside the CIYA-AS nanopore (
FIG. 19 ) were tested to find out which location within the nanopore allows better recognition. As a model system we used human thrombin (HT). When added on the cis side of the nanopore, HT enters the pore and switches between L1 and L2 binidng sites (FIG. 19B ). At high applied potential L2 is populated more than L1 (FIG. 19c ). To test the recognition point in ClyA-AS, we substituted a tryptophan residue (W) to several position inside the nanopore (FIG. 19A ). The occupancy of L1 and L2 at different potentials depended on the mutant tested (FIG. 19C ). Substitutions atposition 49, 56 and 60 had the strongest effect, revealing the potential binding site for HT inside the nanopore. - In addition the binding of analytes to a protein lodged inside the nanopore was tested (
FIG. 20A , SBD2). - We found that the recognition of the substrate is enhanced by placing a tryptophan residue at position 56. Lysine residues at
position 56 or 60 reduced recognition. -
-
Primer name Sequence SEQ ID NO fAlkB AGATATAGCCATGGCGTTGGATCTGTTTGCCGATGCT SEQ ID NO: 22 GAAC AlkBr1 CGGATGGCTCCACGCGCTGCCTTCTTTTTTACCTGCC SEQ ID NO: 23 TGACGGAATG AlkBr2 TATATATAAGCTTATCATTTTTCAAACTGCGGATGGCT SEQ ID NO: 24 CCACGCGCTGCC 120D GCCAGATGCTTGTCTTATCAACCGCTACGCTCCTGGC SEQ ID NO: 25 GCGAAACTGTCGC T7- GCTAGTTATTGCTCAGCGG SEQ ID NO: 26 terminator Anti-AlkB TGCCTAGCGTTTCATTGTCCCTTCTTATTAGGTGATAA SEQ ID NO: 27 aptamer TA DHf atatatatatCCATGGCTTCGGCTATGATTTCTCTGATTG SEQ ID NO: 28 CG DHr CGCGGTTTCTTTCGCTCGAGTACTGCTGCCacggcgttc SEQ ID NO: 29 caggatttcgaatgag Cof ctcattcgaaatcctggaacgccgtGGCAGCAGTACTCGAGC SEQ ID NO: 30 GAAAGAAACCGCG Cor atatatatatAAGCTTATCATTTTTCAAACTGCGGATGGC SEQ ID NO: 31 dcr atatatatatCTCGAGTACTGCTGCCACGGCGTTCCAGG SEQ ID NO: 32 ATTTCG del F atatatatatCTCGAgcgggcAGCGCGTGGAGCCATCCGC SEQ ID NO: 33 AGTTTG 2dcF atatatatatCTCGAGCGaagaagattgcggccctaaaacaggg SEQ ID NO: 34 dcf atatatatatCTCGAGCGaaaaagaagattgcggccctaaaaca SEQ ID NO: 35 ggg Description Sequence Protein MTGIFAEQTVEVVKSAIETADGALDLYNKYLDQVIPWKTFDETIKELSR sequence for S. FKQEYSQEASVLVGDIKVLLMDSQDKYFEATQTVYEWCGVVTQLLSA typhi ClyA YILLFDEYNEKKASAQKDILIRILDDGVKKLNEAQKSLLTSSQSFNNAS (ClyA-WT) GKLLALDSQLTNDFSEKSSYFQSQVDRIRKEAYAGAAAGIVAGPFGLI SEQ ID NO: 1 ISYSIAAGVIEGKLIPELNNRLKTVQNFFTSLSATVKQANKDIDAAKLK LATEIAAIGEIKTETETTRFYVDYDDLMLSLLKGAAKKMINTCNEYQQR HGKKTLFEVPDV Protein MTGIFAEQTVEVVKSAIETADGALDLYNKYLDQVIPWKTFDETIKELSR sequence for FKQEYSQEASVLVGDIKVLLMDSQDKYFEATQTVYEWCGVVTQLLSA ClyA with YIQLFDGYNEKKASAQKDILIRILDDGVKKLNEAQKSLLTSSQSFNNA C285S SGKLLALDSQLTNDFSEKSSYYQSQVDRIRKEAYAGAAAGIVAGPFGL substitution IISYSIAAGVIEGKLIPELNNRLKTVQNFFTSLSATVKQANKDIDAAKLK (ClyA-CS) LATEIAAIGEIKTETETTRFYVDYDDLMLSLLKGAAKKMINTSNEYQQR SEQ ID NO: 2 HGRKTLFEVPDVGSSHHHHHH* Protein MTGIFAEQTVEVVKSAIETADGALDLYNKYLDQVIPWKTFDETIKELSR sequence for FKQEYSQEASVLVGDIKVLLMDSQDKYFEATQTVYEWAGVVTQLLSA ClyA-AS YIQLFDGYNEKKASAQKDILIRILDDGVKKLNEAQKSLLTSSQSFNNA SEQ ID NO: 3 SGKLLALDSQLTNDFSEKSSYYQSQVDRIRKEAYAGAAAGIVAGPFGL IISYSIAAGVVEGKLIPELNNRLKTVQNFFTSLSATVKQANKDIDAAKL KLATEIAAIGEIKTETETTRFYVDYDDLMLSLLKGAAKKMINTSNEYQQ RHGRKTLFEVPDVGSSYHHHHH* Nucleotide CCTGCGTAGATAAGCAGGAAGCAGGCAGTATTTCCAGCTTCTGGAA sequence for S. TGTTAAAGCTACAAAAGTTGTCTGGAGGTAATAGGTAAGAATACTTT typhi ClyA ATAAAACAGGTACTTAATTGCAATTTATATATTTAAAGAGGCAAATG SEQ ID NO: 4 ATTATGACCGGAATATTTGCAGAACAAACTGTAGAGGTAGTTAAAA GCGCGATCGAAACCGCAGATGGGGCATTAGATCTTTATAACAAATA CCTCGACCAGGTCATCCCCTGGAAGACCTTTGATGAAACCATAAAA GAGTTAAGCCGTTTTAAACAGGAGTACTCGCAGGAAGCTTCTGTTT TAGTTGGTGATATTAAAGTTTTGCTTATGGACAGCCAGGACAAGTAT TTTGAAGCGACACAAACTGTTTATGAATGGTGTGGTGTCGTGACGC AATTACTCTCAGCGTATATTTTACTATTTGATGAATATAATGAGAAAA AAGCATCAGCCCAGAAAGACATTCTCATTAGGATATTAGATGATGG TGTCAAGAAACTGAATGAAGCGCAAAAATCTCTCCTGACAAGTTCA CAAAGTTTCAACAACGCTTCCGGAAAACTGCTGGCATTAGATAGCC AGTTAACTAATGATTTTTCGGAAAAAAGTAGTTATTTCCAGTCACAG GTGGATAGAATTCGTAAGGAAGCTTATGCCGGTGCTGCAGCCGGC ATAGTCGCCGGTCCGTTTGGATTAATTATTTCCTATTCTATTGCTGC GGGCGTGATTGAAGGGAAATTGATTCCAGAATTGAATAACAGGCTA AAAACAGTGCAAAATTTCTTTACTAGCTTATCAGCTACAGTGAAACA AGCGAATAAAGATATCGATGCGGCAAAATTGAAATTAGCCACTGAA ATAGCAGCAATTGGGGAGATAAAAACGGAAACCGAAACAACCAGA TTCTACGTTGATTATGATGATTTAATGCTTTCTTTATTAAAAGGAGCT GCAAAGAAAATGATTAACACCTGTAATGAATACCAACAAAGACACG GTAAGAAGACGCTTTTCGAGGTTCCTGACGTCTGATACATTTTCATT CGATCTGTGTACTTTTAACGCCCGATAGCGTAAAGAAAATGAGAGA CGGAGAAAAAGCGATATTCAACAGCCCGATAAACAAGAGTCGTTAC CGGGCTGACGAGGTTATCAGGCGTTAAGCTGGTAG Nucleotide ATGACGGGTATCTTTGCGGAACAGACGGTGGAAGTTGTGAAAAGT sequence for GCGATTGAAACGGCTGACGGTGCGCTGGACCTGTATAATAAATATC ClyA with TGGATCAGGTCATCCCGTGGAAAACCTTTGACGAAACGATTAAAGA C285S ACTGAGCCGTTTCAAACAGGAATACAGTCAAGAAGCGTCCGTCCTG substitution GTGGGCGATATCAAAGTGCTGCTGATGGATTCTCAGGACAAATATT (ClyA-CS) TTGAAGCTACCCAAACGGTTTACGAATGGTGTGGTGTGGTTACCCA SEQ ID NO: 5 GCTGCTGTCCGCATATATTCAGCTGTTCGATGGATACAACGAGAAA AAAGCGAGCGCGCAGAAAGACATTCTGATCCGCATTCTGGATGAC GGCGTGAAAAAACTGAATGAAGCCCAGAAATCGCTGCTGACCAGC TCTCAATCATTTAACAATGCCTCGGGTAAACTGCTGGCACTGGATA GCCAGCTGACGAACGACTTTTCTGAAAAAAGTTCCTATTACCAGAG CCAAGTCGATCGTATTCGTAAAGAAGCCTACGCAGGTGCCGCAGCA GGTATTGTGGCCGGTCCGTTCGGTCTGATTATCTCATATTCGATTG CTGCGGGCGTTATCGAAGGTAAACTGATTCCGGAACTGAACAATCG TCTGAAAACCGTTCAGAACTTTTTCACCAGTCTGTCTGCTACGGTCA AACAAGCGAATAAAGATATCGACGCCGCAAAACTGAAACTGGCCAC GGAAATCGCTGCGATTGGCGAAATCAAAACCGAAACGGAAACCAC GCGCTTTTATGTTGATTACGATGACCTGATGCTGAGCCTGCTGAAA GGTGCCGCGAAGAAAATGATTAATACCTCTAATGAATATCAGCAGC GTCACGGTAGAAAAACCCTGTTTGAAGTCCCGGATGTGGGCAGCA GCCACCACCATCATCACCACTAAAAGCTTGGATCCGGCTGCTAACA AAGCCCGAA Nucleotide ATGACGGGTATCTTTGCGGAACAGACGGTGGAAGTTGTGAAAAGT sequence for GCGATTGAAACGGCTGACGGTGCGCTGGACCTGTATAATAAATATC ClyA-AS TGGATCAGGTCATCCCGTGGAAAACCTTTGACGAAACGATTAAAGA SEQ ID NO: 6 ACTGAGCCGTTTCAAACAGGAATACAGTCAAGAAGCGTCCGTCCTA GTGGGCGATATCAAAGTGCTGCTGATGGATTCTCAGGACAAATATT TTGAAGCTACCCAAACGGTTTACGAATGGGCGGGTGTGGTTACCCA GCTGCTGTCCGCATATATTCAGCTGTTCGATGGATACAATGAGAAA AAAGCGAGCGCGCAGAAAGACATTCTGATCCGCATTCTGGATGAC GGCGTGAAAAAACTGAATGAAGCCCAGAAATCGCTGCTGACCAGC TCTCAATCATTTAACAATGCCTCGGGTAAACTGCTGGCACTGGATA GCCAGCTGACGAACGACTTTTCTGAAAAAAGTTCCTATTACCAGAG CCAAGTCGATCGTATTCGTAAAGAAGCCTACGCAGGTGCCGCAGCA GGTATTGTGGCCGGTCCGTTCGGTCTGATTATCTCATATTCAATTGC TGCGGGCGTTGTCGAAGGTAAACTGATTCCGGAACTGAACAATCGT CTGAAAACCGTTCAGAACTTTTTCACCAGTCTGTCTGCTACGGTCAA ACAAGCGAATAAAGATATCGACGCCGCAAAACTGAAACTGGCCACG GAAATCGCTGCGATTGGCGAAATCAAAACCGAAACGGAAACCACG CGCTTTTATGTTGATTACGATGACCTGATGCTGAGCCTGCTGAAAG GTGCCGCGAAGAAAATGATTAATACCTCTAATGAATATCAGCAGCG TCACGGTAGAAAAACCCTGTTTGAAGTCCCGGATGTGGGCAGCAG CTACCACCATCATCACCACTAAAAGCTT AlkB-streptag MALDLFADAEPWQEPLAAGAVILRRFAFNAAEQLIRDINDVASQSPFR (protein QMVTPGGYTMSVAMTNCGHLGWTTHRQGYLYSPIDPQTNKPWPAM sequence, PQSFHNLCQRAATAAGYPDFQPDACLINRYAPGAKLSLHQDKDEPDL additional RAPIVSVSLGLPAIFQFGGLKRNDPLKRLLLEHGDVVVWGGESRLFYH amino acid GIQPLKAGFHPLTIDCRYNLTFRQAGKKEGSAWSHPQFEK** residues are underlined) SEQ ID NO: 7 >AlkB-streptag Atggcgttggatctgtttgccgatgctgaaccgtggcaagagccactggcggctggtgc (DNA ggtaattttacggcgttttgcttttaacgctgcggagcaactgatccgcgatattaatgac sequence) gttgcagccagtcgccgtttcgccagatggtcacccccgggggatataccatgtcggt SEQ ID NO: 8 ggcgatgaccaactgtgggcatctgggctggacgacccatcggcaaggttatctctatt cgcccattgatccgcaaacaaataaaccgtggcccgccatgccacagagttttcataatt tatgtcaacgtgcggctacggcggcgggctatccagatttccagccagatgcttgtctta tcaaccgctacgctcctggcgcgaaactgtcgctgcatcaggataaagacgaaccgga tctgcgcgcgccaattgtttctgtttctctgggcttacccgcgatttttcaatttggcggcct gaaacgaaatgatccgctcaaacgtttgttgttggaacatggcgatgtggtggtatggg gcggtgaatcgcggctgttttatcacggtattcaaccgttgaaagcggggtttcatccact caccatcgactgccgctacaacctgacattccgtcaggcaggtaaaaaagaaggcagc gcgtggagccatccgcagtttgaaaaatgatAAGCTT >DHFR10+ Atggcttcggctatgatttctctgattgcggcactggctgtcgatcgtgttattggtatgga (DNA aaacgctatgccgtggaatctgccggctgatctggcgtggtttaaacgtaacactctgga sequence) caagccggtcattatgggccgccatacgtgggaaagcatcggtcgtccgctgccgggtc SEQ ID NO: 9 gcaaaaatattatcctgagcagccagccgggcaccgatgaccgtgtgacgtgggttaa gagcgtcgatgaagcaattgcggcggcaggcgacgtgccggaaattatggttatcggc ggtggccgcgtttatgaacagttcctgccgaaagcccaaaagctgtacctgacccatat cgatgcagaagtcgaaggtgatacgcactttccggactatgaaccggatgactgggaa agtgtgttctccgaatttcacgacgccgacgctcagaacagccactcatactcattcgaa atcctggaacgccgtGGCAGCAGTACTCGAGCGAAAGAAACCGCGGCG GCGAAATTTGAACGCCAGCATATGGATAGCGGCAGCGCGAAAATT GCCGCACTTAAACAAAAAATCGCGGCGCTGAAGTATAAAAATGCGG CACTAAAAAAGAAGATTGCGGCCCTAAAACAGGGCAGCGCGTGGA GCCATCCGCAGTTTGAAAAATGATAAGCTTGGA >DHFR10+ MASAMISLIAALAVDRVIGMENAMPWNLPADLAWFKRNTLDKPVIMG (protein RHTWESIGRPLPGRKNIILSSQPGTDDRVTWVKSVDEAIAAAGDVPEI sequence, MVIGGGRVYEQFLPKAQKLYLTHIDAEVEGDTHFPDYEPDDWESVFS additional EFHDADAQNSHSYSFEILERR GSSTRAKETAAAKFERQHMDSGSAKI amino acid AALKQKIAALKYKNAALKKKIAALKQGSAWSHPQFEK** residues are underlined) SEQ ID NO: 10 DHFR10+ ERRGSSTRAKETAAAKFERQHMDSGSAKIAALKQKIAALKYKNAALK SEQ ID NO: 11 KKIAALKQGSAWSHPQFEK DHFRtag ERRGSSTRAKKKIAALKQGSAWSHPQFEK SEQ ID NO: 12 DHFR4+ ERRGSSTRAKKIAALKQGSAWSHPQFEK SEQ ID NO: 13 DHFR ERRGSSTRAGSAWSHPQFEK SEQ ID NO: 14 C-terminus of ERR DHFR S-tag KETAAAKFERQHMDS SEQ ID NO: 16 Positive coil KIAALKQKIAALKYKNAALKKKIAALKQ SEQ ID NO: 17 Strep-tag WSHPQFEK SEQ ID NO: 18 Flexible linker 1 GSSTRA SEQ ID NO: 19 Flexible linker 2 GSA SEQ ID NO: 20 Flexible linker 3 GSSTRAGSA SEQ ID NO: 21
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/487,164 US20220091096A1 (en) | 2015-04-14 | 2021-09-28 | Nanopores with internal protein adaptors |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1506307.6 | 2015-04-14 | ||
GBGB1506307.6A GB201506307D0 (en) | 2015-04-14 | 2015-04-14 | Nanopores with internal protein adaptors |
GBGB1507264.8A GB201507264D0 (en) | 2015-04-29 | 2015-04-29 | Nanopores with internal protein adaptors |
GB1507264.8 | 2015-04-29 | ||
PCT/EP2016/058252 WO2016166232A1 (en) | 2015-04-14 | 2016-04-14 | Nanopores with internal protein adaptors |
US201715566577A | 2017-10-13 | 2017-10-13 | |
US17/487,164 US20220091096A1 (en) | 2015-04-14 | 2021-09-28 | Nanopores with internal protein adaptors |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/058252 Continuation WO2016166232A1 (en) | 2015-04-14 | 2016-04-14 | Nanopores with internal protein adaptors |
US15/566,577 Continuation US11169138B2 (en) | 2015-04-14 | 2016-04-14 | Nanopores with internal protein adaptors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220091096A1 true US20220091096A1 (en) | 2022-03-24 |
Family
ID=55860803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/566,577 Active 2037-05-31 US11169138B2 (en) | 2015-04-14 | 2016-04-14 | Nanopores with internal protein adaptors |
US17/487,164 Pending US20220091096A1 (en) | 2015-04-14 | 2021-09-28 | Nanopores with internal protein adaptors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/566,577 Active 2037-05-31 US11169138B2 (en) | 2015-04-14 | 2016-04-14 | Nanopores with internal protein adaptors |
Country Status (4)
Country | Link |
---|---|
US (2) | US11169138B2 (en) |
EP (1) | EP3283887B1 (en) |
CN (1) | CN107735686B (en) |
WO (1) | WO2016166232A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11572387B2 (en) | 2017-06-30 | 2023-02-07 | Vib Vzw | Protein pores |
US11597970B2 (en) | 2016-03-02 | 2023-03-07 | Oxford Nanopore Technologies Plc | Mutant pores |
US11725235B2 (en) | 2014-01-22 | 2023-08-15 | Oxford Nanopore Technologies Plc | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide |
US11739377B2 (en) | 2014-05-02 | 2023-08-29 | Oxford Nanopore Technologies Plc | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
US11761956B2 (en) | 2013-03-25 | 2023-09-19 | Katholieke Universiteit Leuven | Nanopore biosensors for detection of proteins and nucleic acids |
US11845780B2 (en) | 2012-04-10 | 2023-12-19 | Oxford Nanopore Technologies Plc | Mutant lysenin pores |
US11939359B2 (en) | 2016-04-06 | 2024-03-26 | Oxford Nanopore Technologies Plc | Mutant pore |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
CN117164684A (en) | 2014-09-01 | 2023-12-05 | 弗拉芒区生物技术研究所 | Mutant CSGG wells |
GB201502810D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Method |
US11169138B2 (en) | 2015-04-14 | 2021-11-09 | Katholieke Universiteit Leuven | Nanopores with internal protein adaptors |
AU2016369071B2 (en) | 2015-12-08 | 2022-05-19 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Modified nanopores, compositions comprising the same, and uses thereof |
CA3053086A1 (en) | 2017-02-10 | 2018-08-16 | Oxford Nanopore Technologies Limited | Modified nanopores, compositions comprising the same, and uses thereof |
CN108845003B (en) * | 2018-06-06 | 2020-10-02 | 中国农业大学 | Universal nanopore detection sensor and detection method |
AU2019375476A1 (en) * | 2018-11-08 | 2021-06-03 | Oxford Nanopore Technologies Plc | Pore |
CN110954445B (en) * | 2019-10-31 | 2022-08-16 | 四川大学华西医院 | Living cell biosensor and preparation method and application thereof |
CN112578106B (en) * | 2020-04-13 | 2022-04-22 | 南京大学 | Nano-pore single-molecule protein sequencer |
WO2024078621A1 (en) * | 2022-10-14 | 2024-04-18 | 北京普译生物科技有限公司 | Pht nanopore mutant protein and use thereof |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6362002B1 (en) | 1995-03-17 | 2002-03-26 | President And Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
US5795782A (en) | 1995-03-17 | 1998-08-18 | President & Fellows Of Harvard College | Characterization of individual polymer molecules based on monomer-interface interactions |
JP3891620B2 (en) | 1996-11-14 | 2007-03-14 | 株式会社アイシン・コスモス研究所 | Nucleic acid probe molecule having a hairpin structure, and nucleic acid detection method using the nucleic acid probe molecule |
US20020197614A1 (en) | 1997-05-16 | 2002-12-26 | Mosaic Technologies, Inc. | Electrophoretic analysis of target molecules using adapter molecules |
WO1999005167A1 (en) | 1997-07-25 | 1999-02-04 | University Of Massachusetts | Designed protein pores as components for biosensors |
US6743605B1 (en) | 1998-06-24 | 2004-06-01 | Enzo Life Sciences, Inc. | Linear amplification of specific nucleic acid sequences |
US6267872B1 (en) | 1998-11-06 | 2001-07-31 | The Regents Of The University Of California | Miniature support for thin films containing single channels or nanopores and methods for using same |
US6426231B1 (en) | 1998-11-18 | 2002-07-30 | The Texas A&M University System | Analyte sensing mediated by adapter/carrier molecules |
NO986133D0 (en) | 1998-12-23 | 1998-12-23 | Preben Lexow | Method of DNA Sequencing |
AU5763000A (en) | 1999-06-22 | 2001-01-09 | President And Fellows Of Harvard College | Molecular and atomic scale evaluation of biopolymers |
JP2003508054A (en) | 1999-08-31 | 2003-03-04 | ニーデルバイス,ミヒャエル | Method for producing channel-forming protein |
EP1255772A2 (en) * | 2000-02-11 | 2002-11-13 | The Texas A & M University System | Biosensor compositions and methods of use |
US7001792B2 (en) | 2000-04-24 | 2006-02-21 | Eagle Research & Development, Llc | Ultra-fast nucleic acid sequencing device and a method for making and using the same |
AU2002239284A1 (en) | 2000-11-27 | 2002-06-03 | The Regents Of The University Of California | Methods and devices for characterizing duplex nucleic acid molecules |
US6863833B1 (en) | 2001-06-29 | 2005-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Microfabricated apertures for supporting bilayer lipid membranes |
WO2003095669A1 (en) | 2002-05-10 | 2003-11-20 | The Texas A & M University System | Stochastic sensing through covalent interactions |
WO2004087868A2 (en) | 2003-03-25 | 2004-10-14 | Stratagene | Dna polymerase fusions and uses thereof |
US7163658B2 (en) | 2003-04-23 | 2007-01-16 | Rouvain Bension | Rapid sequencing of polymers |
JP2005253427A (en) | 2004-03-15 | 2005-09-22 | Aisin Seiki Co Ltd | Method for detecting nucleic acid and method for isolating nucleic acid |
WO2006028508A2 (en) | 2004-03-23 | 2006-03-16 | President And Fellows Of Harvard College | Methods and apparatus for characterizing polynucleotides |
US20060105461A1 (en) | 2004-10-22 | 2006-05-18 | May Tom-Moy | Nanopore analysis system |
EP1842061A4 (en) | 2004-12-21 | 2009-05-13 | Texas A & M Univ Sys | High temperature ion channels and pores |
GB0505971D0 (en) | 2005-03-23 | 2005-04-27 | Isis Innovation | Delivery of molecules to a lipid bilayer |
KR100730350B1 (en) | 2005-10-17 | 2007-06-19 | 삼성전자주식회사 | Method for short DNA detection using surface functionalized nanopore, and Detection Apparatus therefor |
GB0523282D0 (en) | 2005-11-15 | 2005-12-21 | Isis Innovation | Methods using pores |
US8936926B2 (en) | 2005-12-22 | 2015-01-20 | Pacific Biosciences Of California | Active surface coupled polymerases |
US7638034B2 (en) | 2006-09-21 | 2009-12-29 | Los Alamos National Security, Llc | Electrochemical detection of single molecules using abiotic nanopores having electrically tunable dimensions |
EP2122344B8 (en) | 2007-02-20 | 2019-08-21 | Oxford Nanopore Technologies Limited | Lipid bilayer sensor system |
AU2008236694B2 (en) | 2007-04-04 | 2014-01-23 | The Regents Of The University Of California | Compositions, devices, systems, and methods for using a nanopore |
GB0716264D0 (en) | 2007-08-21 | 2007-09-26 | Isis Innovation | Bilayers |
EP2195648B1 (en) | 2007-09-12 | 2019-05-08 | President and Fellows of Harvard College | High-resolution molecular graphene sensor comprising an aperture in the graphene layer |
GB2453377A (en) | 2007-10-05 | 2009-04-08 | Isis Innovation | Transmembrane protein pores and molecular adapters therefore. |
GB0724736D0 (en) | 2007-12-19 | 2008-01-30 | Oxford Nanolabs Ltd | Formation of layers of amphiphilic molecules |
US8231969B2 (en) | 2008-03-26 | 2012-07-31 | University Of Utah Research Foundation | Asymmetrically functionalized nanoparticles |
CN104862383B (en) | 2008-03-28 | 2019-05-28 | 加利福尼亚太平洋生物科学股份有限公司 | Composition and method for nucleic acid sequencing |
WO2009143425A1 (en) | 2008-05-22 | 2009-11-26 | The Regents Of The University Of California | Membrane precursors and membranes formed therefrom |
US8652771B2 (en) | 2008-05-28 | 2014-02-18 | University of Souther California | Measurement of succinate in urine samples as a biomarker of kidney damage in diabetic subjects |
WO2010004265A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Enzyme-pore constructs |
CN102144037A (en) | 2008-07-07 | 2011-08-03 | 牛津纳米孔技术有限公司 | Base-detecting pore |
CN102216783B (en) | 2008-09-22 | 2015-04-01 | 华盛顿大学 | MSP nanopores and related methods |
US9080211B2 (en) | 2008-10-24 | 2015-07-14 | Epicentre Technologies Corporation | Transposon end compositions and methods for modifying nucleic acids |
GB0820927D0 (en) * | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
WO2010086603A1 (en) | 2009-01-30 | 2010-08-05 | Oxford Nanopore Technologies Limited | Enzyme mutant |
CN102369298B (en) | 2009-01-30 | 2017-03-22 | 牛津纳米孔技术有限公司 | Adaptors for nucleic acid constructs in transmembrane sequencing |
GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
DK2422198T3 (en) | 2009-04-20 | 2014-01-06 | Oxford Nanopore Tech Ltd | Lipid bilayers SENSOR GROUP |
JP5873023B2 (en) | 2009-12-01 | 2016-03-01 | オックスフォード ナノポール テクノロジーズ リミテッド | Biochemical analyzer |
EP2539465B1 (en) | 2010-02-23 | 2024-03-06 | University Of Washington | Analyte sequencing with nanopores |
EP2556085A2 (en) | 2010-04-05 | 2013-02-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
US9593370B2 (en) | 2010-10-01 | 2017-03-14 | Oxford Nanopore Technologies Ltd. | Biochemical analysis apparatus and rotary valve |
CN102116783B (en) | 2010-12-31 | 2013-05-29 | 北京普源精电科技有限公司 | Waveform display method |
CN102174554A (en) | 2011-01-24 | 2011-09-07 | 内蒙古民族大学 | Double-control double-regulation prokaryotic expression vector system and construction method and application thereof |
US9751915B2 (en) | 2011-02-11 | 2017-09-05 | Oxford Nanopore Technologies Ltd. | Mutant pores |
AU2012264497B2 (en) | 2011-05-27 | 2017-06-15 | Oxford Nanopore Technologies Limited | Coupling method |
US9580480B2 (en) | 2011-05-31 | 2017-02-28 | Massachusetts Institute Of Technology | Cell-directed synthesis of multifunctional nanopatterns and nanomaterials |
IN2014DN00221A (en) | 2011-07-25 | 2015-06-05 | Oxford Nanopore Tech Ltd | |
US20160162634A1 (en) | 2011-09-23 | 2016-06-09 | Oxford Nanopore Technologies Limited | Analysis of a polymer comprising polymer units |
EP2987870B1 (en) | 2011-10-21 | 2020-02-19 | Oxford Nanopore Technologies Limited | Method of characterizing a target polynucleotide using a transmembrane pore and molecular motor |
WO2013098562A2 (en) | 2011-12-29 | 2013-07-04 | Oxford Nanopore Technologies Limited | Enzyme method |
CN104136631B (en) | 2011-12-29 | 2017-03-01 | 牛津纳米孔技术公司 | Method using XPD unwindase characterising polynucleotides |
JP6333179B2 (en) | 2012-01-20 | 2018-05-30 | ジニア テクノロジーズ, インコーポレイテッド | Nanopore-based molecular detection and sequencing |
WO2013121201A1 (en) | 2012-02-15 | 2013-08-22 | Oxford Nanopore Technologies Limited | Aptamer method |
EP2836506B1 (en) | 2012-04-10 | 2017-04-19 | Oxford Nanopore Technologies Limited | Mutant lysenin pores |
TWI655213B (en) | 2012-07-13 | 2019-04-01 | 目立康股份有限公司 | Method for producing self-organizing peptide derivative |
EP2875154B1 (en) | 2012-07-19 | 2017-08-23 | Oxford Nanopore Technologies Limited | SSB method for characterising a nucleic acid |
US9797009B2 (en) | 2012-07-19 | 2017-10-24 | Oxford Nanopore Technologies Limited | Enzyme construct |
EP2875128B8 (en) | 2012-07-19 | 2020-06-24 | Oxford Nanopore Technologies Limited | Modified helicases |
CN104936682B (en) | 2012-10-26 | 2017-12-15 | 牛津纳米孔技术公司 | Droplet interface |
GB201313121D0 (en) | 2013-07-23 | 2013-09-04 | Oxford Nanopore Tech Ltd | Array of volumes of polar medium |
US10179933B2 (en) * | 2013-02-07 | 2019-01-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Hybrid nanopores and uses thereof for detection of analytes |
EP2964779B1 (en) | 2013-03-08 | 2018-08-29 | Oxford Nanopore Technologies Limited | Use of spacer elements in a nucleic acid to control movement of a helicase |
GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
US10613076B2 (en) * | 2013-03-14 | 2020-04-07 | The Trustees Of Boston University | Optoelectronic control of solid-state nanopores |
GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
WO2015051378A1 (en) | 2013-10-04 | 2015-04-09 | University Of Washington Through Its Center For Commercialization | Systems and methods for nanopore-based analysis of nucleic acids |
CN105899678A (en) | 2013-10-18 | 2016-08-24 | 牛津纳米孔技术公司 | Modified enzymes |
GB201406151D0 (en) | 2014-04-04 | 2014-05-21 | Oxford Nanopore Tech Ltd | Method |
GB201406155D0 (en) | 2014-04-04 | 2014-05-21 | Oxford Nanopore Tech Ltd | Method |
WO2015110813A1 (en) | 2014-01-22 | 2015-07-30 | Oxford Nanopore Technologies Limited | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide |
GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
US10337060B2 (en) | 2014-04-04 | 2019-07-02 | Oxford Nanopore Technologies Ltd. | Method for characterising a double stranded nucleic acid using a nano-pore and anchor molecules at both ends of said nucleic acid |
CN106459159B (en) | 2014-05-02 | 2021-11-30 | 牛津纳米孔技术公司 | Abrupt change hole |
FR3023394B1 (en) | 2014-07-02 | 2017-12-29 | Adn Access Data Networks | DEVICE FOR FACILITATING THE TEACHING OF THE AMBARIC LANGUAGE AND NORMALIZING THE WRITING |
CN117164684A (en) | 2014-09-01 | 2023-12-05 | 弗拉芒区生物技术研究所 | Mutant CSGG wells |
WO2016055778A1 (en) | 2014-10-07 | 2016-04-14 | Oxford Nanopore Technologies Limited | Mutant pores |
GB201502810D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Method |
GB201502809D0 (en) | 2015-02-19 | 2015-04-08 | Oxford Nanopore Tech Ltd | Mutant pore |
US11169138B2 (en) | 2015-04-14 | 2021-11-09 | Katholieke Universiteit Leuven | Nanopores with internal protein adaptors |
AU2016369071B2 (en) | 2015-12-08 | 2022-05-19 | Katholieke Universiteit Leuven Ku Leuven Research & Development | Modified nanopores, compositions comprising the same, and uses thereof |
CN116200476A (en) | 2016-03-02 | 2023-06-02 | 牛津纳米孔科技公开有限公司 | Target analyte determination methods, mutant CsgG monomers, constructs, polynucleotides and oligo-wells thereof |
CA3212147A1 (en) | 2016-04-06 | 2017-10-12 | Oxford Nanopore Technologies Plc | Mutant pore |
-
2016
- 2016-04-14 US US15/566,577 patent/US11169138B2/en active Active
- 2016-04-14 WO PCT/EP2016/058252 patent/WO2016166232A1/en active Application Filing
- 2016-04-14 EP EP16719292.1A patent/EP3283887B1/en active Active
- 2016-04-14 CN CN201680034399.2A patent/CN107735686B/en active Active
-
2021
- 2021-09-28 US US17/487,164 patent/US20220091096A1/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11845780B2 (en) | 2012-04-10 | 2023-12-19 | Oxford Nanopore Technologies Plc | Mutant lysenin pores |
US11761956B2 (en) | 2013-03-25 | 2023-09-19 | Katholieke Universiteit Leuven | Nanopore biosensors for detection of proteins and nucleic acids |
US11725235B2 (en) | 2014-01-22 | 2023-08-15 | Oxford Nanopore Technologies Plc | Method for attaching one or more polynucleotide binding proteins to a target polynucleotide |
US11739377B2 (en) | 2014-05-02 | 2023-08-29 | Oxford Nanopore Technologies Plc | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
US11597970B2 (en) | 2016-03-02 | 2023-03-07 | Oxford Nanopore Technologies Plc | Mutant pores |
US11685949B2 (en) | 2016-03-02 | 2023-06-27 | Oxford Nanopore Technologies Plc | Mutant pore |
US11939359B2 (en) | 2016-04-06 | 2024-03-26 | Oxford Nanopore Technologies Plc | Mutant pore |
US11572387B2 (en) | 2017-06-30 | 2023-02-07 | Vib Vzw | Protein pores |
US11945840B2 (en) | 2017-06-30 | 2024-04-02 | Vib Vzw | Protein pores |
Also Published As
Publication number | Publication date |
---|---|
CN107735686B (en) | 2021-06-11 |
EP3283887B1 (en) | 2021-07-21 |
US20180209952A1 (en) | 2018-07-26 |
EP3283887A1 (en) | 2018-02-21 |
US11169138B2 (en) | 2021-11-09 |
CN107735686A (en) | 2018-02-23 |
WO2016166232A1 (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220091096A1 (en) | Nanopores with internal protein adaptors | |
US11761956B2 (en) | Nanopore biosensors for detection of proteins and nucleic acids | |
JP7027334B2 (en) | Alpha hemolysin variants and their use | |
JP6975185B2 (en) | Long-life alpha hemolysin nanopore | |
US20220242922A1 (en) | Biological Nanopores for Biopolymer Sensing and Sequencing Based on FRAC Actinoporin | |
JP2020530276A (en) | New protein pores | |
JP2010539966A (en) | Molecular adapter | |
JP2022500074A (en) | Biological nanopores with adjustable pore diameter and their use as analytical tools | |
JP2021514634A (en) | Alpha hemolysin variant and its use | |
US20240036027A1 (en) | Nanopore Biosensors and Uses Thereof | |
WO2024089270A2 (en) | Pore monomers and pores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAGLIA, GIOVANNI;SOSKINE, MIKHAEL;BIESEMANS, ANNEMIE;AND OTHERS;SIGNING DATES FROM 20170314 TO 20170606;REEL/FRAME:066915/0712 Owner name: RIJKSUNIVERSITEIT GRONINGEN, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POOLMAN, BERT;SCHUURMAN-WOLTERS, GEA;SIGNING DATES FROM 20170406 TO 20170418;REEL/FRAME:066915/0795 |